Steven A. Rosenberg - Publications

Affiliations: 
NCI/NIH, Bethesda, MD, United States 

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, Gartner JJ, Sindiri S, Malekzadeh P, Deniger DC, Lowery FJ, Parkhurst MR, Ngo LT, Ray S, Li YF, ... ... Rosenberg SA, et al. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. Cancer Immunology Research. OF1-OF15. PMID 35749374 DOI: 10.1158/2326-6066.CIR-22-0040  0.472
2022 Seitter SJ, McClelland PH, Ahlman MA, Goff SL, Yang JC, McIntyre L, Rosenberg SA, Kochenderfer JN, Brudno JN. Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience. Leukemia & Lymphoma. 1-5. PMID 35679521 DOI: 10.1080/10428194.2022.2076853  0.327
2022 Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih YP, Leung A, Payne R, Sutcliffe K, Cramer J, Rosenberg SA, Fox BA, Urba WJ, Tran E. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. The New England Journal of Medicine. 386: 2112-2119. PMID 35648703 DOI: 10.1056/NEJMoa2119662  0.483
2022 Hanada KI, Zhao C, Gil-Hoyos R, Gartner JJ, Chow-Parmer C, Lowery FJ, Krishna S, Prickett TD, Kivitz S, Parkhurst MR, Wong N, Rae Z, Kelly MC, Goff SL, Robbins PF, ... Rosenberg SA, et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell. PMID 35452604 DOI: 10.1016/j.ccell.2022.03.012  0.491
2022 Levi ST, Copeland AR, Nah S, Crystal JS, Ivey GD, Lalani A, Jafferji M, White BS, Parikh NB, Leko V, Krishna S, Lowery F, Prickett TD, Gartner JJ, Jia L, ... ... Rosenberg SA, et al. Neoantigen Identification and Response to Adoptive Cell Transfer in anti PD-1 Naïve and Experienced Patients with Metastatic Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35247926 DOI: 10.1158/1078-0432.CCR-21-4499  0.353
2022 Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, Parkhurst MR, Levin N, Sindiri S, Sachs A, Hitscherich KJ, Yu Z, Vale NR, Lu YC, Zheng Z, ... ... Rosenberg SA, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science (New York, N.Y.). eabl5447. PMID 35113651 DOI: 10.1126/science.abl5447  0.494
2021 Gartner JJ, Parkhurst MR, Gros A, Tran E, Jafferji MS, Copeland A, Hanada KI, Zacharakis N, Lalani A, Krishna S, Sachs A, Prickett TD, Li YF, Florentin M, Kivitz S, ... ... Rosenberg SA, et al. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. Nature Cancer. 2: 563-574. PMID 34927080 DOI: 10.1038/s43018-021-00197-6  0.336
2021 Peri A, Greenstein E, Alon M, Pai JA, Dingjan T, Reich-Zeliger S, Barnea E, Barbolin C, Levy R, Arnedo-Pac C, Kalaora S, Dassa B, Feldmesser E, Shang P, Greenberg P, ... ... Rosenberg SA, et al. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. The Journal of Clinical Investigation. 131. PMID 34651586 DOI: 10.1172/JCI129466  0.446
2021 Seitter SJ, Sherry RM, Yang JC, Robbins PF, Shindorf ML, Copeland AR, McGowan CT, Epstein M, Shelton TE, Langhan MM, Franco Z, Danforth DN, White DE, Rosenberg SA, Goff SL. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34413159 DOI: 10.1158/1078-0432.CCR-21-1171  0.331
2021 Lu YC, Zheng Z, Lowery FJ, Gartner JJ, Prickett TD, Robbins PF, Rosenberg SA. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. Journal For Immunotherapy of Cancer. 9. PMID 34321276 DOI: 10.1136/jitc-2021-002595  0.357
2021 Leko V, Cafri G, Yossef R, Paria B, Hill V, Gurusamy D, Zheng Z, Gartner JJ, Prickett TD, Goff SL, Robbins P, Lu YC, Rosenberg SA. Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma. Journal For Immunotherapy of Cancer. 9. PMID 34266885 DOI: 10.1136/jitc-2021-002882  0.394
2021 Levin N, Paria BC, Vale NR, Yoseph R, Lowery FJ, Parkhurst MR, Yu Z, Florentin M, Cafri G, Gartner JJ, Shindorf ML, Ngo LT, Ray S, Kim SP, Copeland AR, ... ... Rosenberg SA, et al. Identification and validation of T-cell receptors targeting RAS hot-spot mutations in human cancers for use in cell-based immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34168045 DOI: 10.1158/1078-0432.CCR-21-0849  0.323
2020 Paria BC, Levin N, Lowery FJ, Pasetto A, Deniger DC, Parkhurst MR, Yossef R, Kim SP, Florentin M, Ngo LT, Ray S, Krishna S, Robbins PF, Rosenberg SA. Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 33086340 DOI: 10.1097/CJI.0000000000000342  0.313
2020 Leko V, Rosenberg SA. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. Cancer Cell. PMID 32822573 DOI: 10.1016/j.ccell.2020.07.013  0.473
2020 Sachs A, Moore E, Kosaloglu-Yalcin Z, Peters B, Sidney J, Rosenberg SA, Robbins PF, Sette A. Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells. Journal of Immunology (Baltimore, Md. : 1950). PMID 32571843 DOI: 10.4049/jimmunol.1901173  0.396
2020 Sim MJW, Lu J, Spencer M, Hopkins F, Tran E, Rosenberg SA, Long EO, Sun PD. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. Proceedings of the National Academy of Sciences of the United States of America. PMID 32461371 DOI: 10.1073/pnas.1921964117  0.441
2020 Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, ... ... Rosenberg SA, et al. Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Medicine. PMID 32291416 DOI: 10.1038/S41591-020-0864-X  0.382
2020 Kalaora S, Lee JS, Barnea E, Levy R, Greenberg P, Alon M, Yagel G, Bar Eli G, Oren R, Peri A, Patkar S, Bitton L, Rosenberg SA, Lotem M, Levin Y, et al. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nature Communications. 11: 896. PMID 32060274 DOI: 10.1038/S41467-020-14639-9  0.428
2020 Malekzadeh P, Yossef R, Cafri G, Paria BC, Lowery FJ, Jafferji M, Good ML, Sachs A, Copeland AR, Kim SP, Kivitz S, Parkhurst MR, Robbins PF, Ray S, Xi L, ... ... Rosenberg SA, et al. Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31996390 DOI: 10.1158/1078-0432.Ccr-19-1874  0.39
2020 Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, ... ... Rosenberg SA, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Medicine. PMID 31959992 DOI: 10.1038/S41591-019-0737-3  0.459
2020 Zhang L, Davies JS, Serna C, Yu Z, Restifo NP, Rosenberg SA, Morgan RA, Hinrichs CS. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. Journal For Immunotherapy of Cancer. 8. PMID 31959727 DOI: 10.1136/Jitc-2019-000210  0.363
2020 Cappell K, Sherry RM, Yang JC, Goff SL, Vanasse D, McIntyre L, Rosenberg SA, Kochenderfer JN. Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma and chronic lymphocytic leukemia. Journal of Clinical Oncology. 38: 3012-3012. DOI: 10.1200/jco.2020.38.15_suppl.3012  0.448
2020 Rosenberg S. Abstract IA24: T cells as a drug for the personalized immunotherapy of cancer Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-Ia24  0.467
2020 Yang J, Hanada K, Rosenberg S. Abstract IA15: T-Cells targeting mutated RAS—clinical trials Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-Ia15  0.415
2020 Zacharakis N, Kim P, Robbins P, Gartner J, Prickett T, Hill V, Paria B, Feldman S, Goff S, Rosenberg S. Abstract 1068: Tumor infiltrating lymphocytes (TIL) recognize a unique and diverse number of non-synonymous somatic mutations in patients with metastatic breast cancer Cancer Research. 80: 1068-1068. DOI: 10.1158/1538-7445.Am2020-1068  0.436
2019 Gros A, Tran E, Parkhurst MR, Ilyas S, Pasetto A, Groh EM, Robbins PF, Yossef R, Garcia-Garijo A, Fajardo CA, Prickett TD, Jia L, Gartner JJ, Ray S, Ngo L, ... ... Rosenberg SA, et al. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. The Journal of Clinical Investigation. PMID 31609250 DOI: 10.1172/JCI127967  0.414
2019 Lu YC, Jia L, Zheng Z, Tran E, Robbins PF, Rosenberg SA. Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy. Cancer Immunology Research. PMID 31484655 DOI: 10.1158/2326-6066.CIR-19-0299  0.462
2019 Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802424. PMID 31408414 DOI: 10.1200/JCO.18.02424  0.389
2019 Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, Crystal JS, Sachs A, Groh EM, Ray S, Ngo LT, ... Rosenberg SA, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discovery. PMID 31164343 DOI: 10.1158/2159-8290.CD-18-1494  0.458
2019 Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett TD, Apolo AB, Agarwal PK, Rosenberg SA, Lu YC. Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. Journal of Immunology (Baltimore, Md. : 1950). PMID 31036766 DOI: 10.4049/jimmunol.1801022  0.446
2019 Sana G, Madigan JP, Gartner JJ, Fourrez M, Lin J, Qutob N, Narayan J, Shukla S, Ambudkar SV, Xia D, Rosenberg SA, Gottesman MM, Samuels Y, Gillet JP. Exome sequencing of ABCB5 identifies recurrent melanoma mutations that result in increased proliferative and invasive capacities. The Journal of Investigative Dermatology. PMID 30905807 DOI: 10.1016/j.jid.2019.01.036  0.304
2019 Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, ... Rosenberg SA, et al. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 30882547 DOI: 10.1097/Cji.0000000000000260  0.453
2019 Goff SL, Rosenberg SA. BRAF inhibition: Bridge or boost to T cell therapy? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30824585 DOI: 10.1158/1078-0432.CCR-19-0286  0.427
2019 Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. The Journal of Clinical Investigation. PMID 30714987 DOI: 10.1172/Jci123791  0.447
2019 Lo W, Parkhurst MR, Robbins PF, Tran E, Lu YC, Jia L, Gartner JJ, Pasetto A, Deniger DC, Malekzadeh P, Shelton T, Prickett TD, Ray S, Kivitz S, Paria BC, ... ... Rosenberg SA, et al. Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunology Research. PMID 30709841 DOI: 10.1158/2326-6066.CIR-18-0686  0.416
2019 Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nature Communications. 10: 449. PMID 30683863 DOI: 10.1038/s41467-019-08304-z  0.458
2019 Ahmadzadeh M, Pasetto A, Jia L, Deniger DC, Stevanović S, Robbins PF, Rosenberg SA. Tumor-infiltrating human CD4 regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Science Immunology. 4. PMID 30635355 DOI: 10.1126/sciimmunol.aao4310  0.505
2019 Cafri G, Gartner JJ, Hopson K, Meehan RS, Zaks TZ, Robbins P, Rosenberg SA. Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer. Journal of Clinical Oncology. 37: 2643-2643. DOI: 10.1200/Jco.2019.37.15_Suppl.2643  0.432
2019 Rosenberg SA. Abstract IA14: Cell transfer immunotherapy targeting unique somatic mutations in cancer Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Ia14  0.456
2019 Yossef R, Tran E, Gros A, Deniger D, Cafri G, Rosenberg SA. Abstract B055: Enhanced detection of T-cells targeting unique neoantigens and shared mutated oncogenes for personalized cancer immunotherapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B055  0.494
2019 Cafri G, Yossef R, Pasetto A, Deniger D, Gartner JJ, Prickett T, Robbins PF, Rosenberg SA. Abstract A175: Memory T-cells targeting unique and shared oncogenic mutations detected in peripheral blood of epithelial cancer patients Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A175  0.443
2018 Stevanovic S, Helman SR, Wunderlich JR, Doran SL, Langhan MM, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula U, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30518633 DOI: 10.1158/1078-0432.CCR-18-2722  0.379
2018 Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, Rosenberg SA. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. Jci Insight. 3. PMID 30282837 DOI: 10.1172/jci.insight.122467  0.502
2018 Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, ... ... Rosenberg SA, et al. Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Molecular Therapy. Methods & Clinical Development. 10: 371-378. PMID 30211249 DOI: 10.1016/J.Omtm.2018.08.006  0.321
2018 Samuels Y, Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, ... Rosenberg SA, et al. Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma. Cancer Discovery. PMID 30209080 DOI: 10.1158/2159-8290.Cd-17-1418  0.487
2018 Rossi J, Paczkowski P, Shen YW, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath JR, Rosenberg SA, Kochenderfer JN, Zhou J, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL. Blood. PMID 29895668 DOI: 10.1182/Blood-2018-01-828343  0.443
2018 Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, ... Rosenberg SA, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nature Medicine. PMID 29867227 DOI: 10.1038/s41591-018-0040-8  0.37
2018 Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, Malekzadeh P, Jia L, Yossef R, Langhan MM, Wunderlich JR, Danforth DN, Somerville RPT, Rosenberg SA. T-cell responses to "hotspot" mutations and unique neoantigens expressed by human ovarian cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29853601 DOI: 10.1158/1078-0432.CCR-18-0573  0.39
2018 Mehta GU, Malekzadeh P, Shelton T, White DE, Butman JA, Yang JC, Kammula US, Goff SL, Rosenberg SA, Sherry RM. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 29672342 DOI: 10.1097/CJI.0000000000000223  0.322
2018 Qutob N, Masuho I, Alon M, Emmanuel R, Cohen I, Di Pizio A, Madore J, Elkahloun A, Ziv T, Levy R, Gartner JJ, Hill VK, Lin JC, Hevroni Y, Greenberg P, ... ... Rosenberg SA, et al. RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. Scientific Reports. 8: 653. PMID 29330521 DOI: 10.1038/S41598-017-18851-4  0.304
2018 Doran SL, Stevanovic S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Feldman S, Somerville R, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. Genetically engineered T-cell therapy for HPV-associated epithelial cancers: A first in human, phase I/II clinical trial. Journal of Clinical Oncology. 36: 3019-3019. DOI: 10.1200/JCO.2018.36.15_SUPPL.3019  0.342
2018 Stevanovic S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RP, Klebanoff CA, Kammula U, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells. Journal of Clinical Oncology. 36: 3004-3004. DOI: 10.1200/JCO.2018.36.15_SUPPL.3004  0.398
2017 Lu YC, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V, Fitzgerald PC, Rosenberg SA. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29174843 DOI: 10.1016/j.ymthe.2017.10.018  0.489
2017 Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, ... Rosenberg SA, et al. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017745463. PMID 28809608 DOI: 10.1200/JCO.2017.74.5463  0.491
2017 Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, McIntyre L, Bot A, Rossi J, Lam N, Rosenberg SA. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28803861 DOI: 10.1016/J.Ymthe.2017.07.004  0.405
2017 Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science (New York, N.Y.). 356: 200-205. PMID 28408606 DOI: 10.1126/Science.Aak9510  0.495
2017 Chandran SS, Somerville RP, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, ... ... Rosenberg SA, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. The Lancet. Oncology. PMID 28395880 DOI: 10.1016/S1470-2045(17)30251-6  0.376
2017 Assadipour Y, Zacharakis N, Crystal JS, Prickett TD, Gartner JJ, Somerville RP, Xu H, Black MA, Jia L, Chinnasamy H, Kriley I, Lu L, Wunderlich JR, Zheng Z, Lu YC, ... ... Rosenberg SA, et al. Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28377481 DOI: 10.1158/1078-0432.CCR-16-1423  0.396
2017 Kochenderfer JN, Somerville RP, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, ... Rosenberg SA, et al. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016713024. PMID 28291388 DOI: 10.1200/Jco.2016.71.3024  0.46
2017 Qiao G, Qin J, Kunda N, Calata J, Mahmud D, Gann PH, Fu YX, Rosenberg SA, Prabhakar BS, Maker AV. LIGHT elevation enhances immune eradication of colon cancer metastases. Cancer Research. PMID 28249900 DOI: 10.1158/0008-5472.Can-16-1655  0.432
2017 Tran E, Robbins PF, Rosenberg SA. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nature Immunology. 18: 255-262. PMID 28198830 DOI: 10.1038/ni.3682  0.427
2017 Deniger DC, Kwong ML, Pasetto A, Dudley ME, Wunderlich JR, Langhan MM, Lee CR, Rosenberg SA. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 351-362. PMID 28093487 DOI: 10.1158/1078-0432.CCR-16-0906  0.394
2017 Hinrichs CS, Doran SL, Stevanovic S, Adhikary S, Mojadidi M, Kwong ML, Faquin WC, Feldman S, Somerville R, Sherry RM, Yang JC, Rosenberg SA. A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers. Journal of Clinical Oncology. 35: 3009-3009. DOI: 10.1200/JCO.2017.35.15_SUPPL.3009  0.483
2017 Goff S, Zacharakis N, Assadipour Y, Prickett T, Gartner J, Somerville R, Black M, Xu H, Chinnasamy H, Kriley I, Lu L, Statler M, Wunderlich J, Robbins P, Rosenberg S, et al. Abstract P2-04-02: Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P2-04-02  0.348
2017 Arafeh R, Qutob N, Emmanuel RR, Madore J, Elkahloun A, Wilmott JSJS, Gartner JJ, Pizio AD, Rotkopf R, Dutton-Regester K, Hill V, Pritchard A, Lin JC, Rosenberg SA, Khan J, et al. Abstract LB-031: Deciphering distinct roles of RASA2 in melanomagenesis Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-031  0.315
2017 Zacharakis N, Trebska-McGowan K, Somerville R, Lu Y, Pasetto A, Black M, Chinnasamy H, Xu H, Gartner JJ, Prickett TD, Robbins PF, Rosenberg SA, Goff SL, Feldman SA. Abstract 4982: Regression of metastatic breast cancer after adoptive cell transfer of tumor infiltrating lymphocytes and checkpoint blockade Cancer Research. 77: 4982-4982. DOI: 10.1158/1538-7445.Am2017-4982  0.476
2017 Rossi J, Paczkowski P, Shen Y, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath J, Rosenberg SA, Kochenderfer JN, Zhou J, et al. Abstract 2990: Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin’s lymphoma Cancer Research. 77: 2990-2990. DOI: 10.1158/1538-7445.Am2017-2990  0.46
2016 Slaney CY, von Scheidt B, Davenport AJ, Beavis P, Westwood JA, Mardiana S, Tscharke D, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, ... Rosenberg SA, et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27965307 DOI: 10.1158/1078-0432.Ccr-16-1860  0.451
2016 Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. The New England Journal of Medicine. 375: 2255-2262. PMID 27959684 DOI: 10.1056/NEJMoa1609279  0.478
2016 Lu TL, Pugach O, Somerville RP, Rosenberg SA, Kochenderfer JN, Better M, Feldman SA. A RAPID CELL EXPANSION PROCESS FOR PRODUCTION OF ENGINEERED AUTOLOGOUS CAR-T CELL THERAPIES. Human Gene Therapy Methods. PMID 27897048 DOI: 10.1089/hgtb.2016.120  0.41
2016 Parkhurst MR, Gros A, Pasetto A, Prickett TD, Crystal JS, Robbins PF, Rosenberg SA. Isolation of T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes based on CD137 expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27827318 DOI: 10.1158/1078-0432.CCR-16-2680  0.486
2016 Klemen ND, Feingold PL, Goff SL, Hughes MS, Kammula US, Yang JC, Schrump DS, Rosenberg SA, Sherry RM. Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. Annals of Surgical Oncology. PMID 27638681 DOI: 10.1245/s10434-016-5537-0  0.377
2016 Xi L, Pham T, Payabyab EC, Sherry RM, Rosenberg SA, Raffeld M. Circulating Tumor DNA as an Early Indicator of Response to T-Cell Transfer Immunotherapy in Metastatic Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27482033 DOI: 10.1158/1078-0432.CCR-16-0613  0.432
2016 Pasetto A, Alena G, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemos R, Douek DC, Howie B, Robins H, Parkhurst MR, Gartner JJ, Trebska-McGowan K, Crystal JS, Rosenberg SA. Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunology Research. PMID 27354337 DOI: 10.1158/2326-6066.Cir-16-0001  0.506
2016 Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF. Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunology Research. PMID 27312342 DOI: 10.1158/2326-6066.CIR-15-0215  0.502
2016 Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, ... ... Rosenberg SA, et al. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27217459 DOI: 10.1200/Jco.2016.66.7220  0.423
2016 Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 39: 191-201. PMID 27163739 DOI: 10.1097/CJI.0000000000000123  0.487
2016 Kerkar SP, Wang ZF, Lasota J, Park T, Patel K, Groh E, Rosenberg SA, Miettinen MM. MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. Journal of Immunotherapy (Hagerstown, Md. : 1997). 39: 181-7. PMID 27070449 DOI: 10.1097/CJI.0000000000000119  0.314
2016 Deniger DC, Pasetto A, Tran E, Parkhurst MR, Cohen CJ, Robbins PF, Cooper LJ, Rosenberg SA. Stable, non-viral expression of mutated tumor neoantigen-specific T-cell receptors using the Sleeping Beauty transposon/transposase system. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26945006 DOI: 10.1038/mt.2016.51  0.475
2016 Jaigirdar A, Rosenberg SA, Parkhurst M. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 26938944 DOI: 10.1097/CJI.0000000000000116  0.496
2016 Yang JC, Rosenberg SA. Adoptive T-Cell Therapy for Cancer. Advances in Immunology. 130: 279-294. PMID 26923004 DOI: 10.1016/bs.ai.2015.12.006  0.466
2016 Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nature Medicine. PMID 26901407 DOI: 10.1038/nm.4051  0.463
2016 Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A, Samuels Y. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget. PMID 26819371 DOI: 10.18632/oncotarget.6960  0.413
2016 Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL, Feldman SA, Iwamoto AT, Kurlander R, Maric I, Goy A, ... ... Rosenberg SA, et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26811520 DOI: 10.1200/JCO.2015.64.5929  0.346
2016 Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine. 22: 26-36. PMID 26735408 DOI: 10.1038/Nm.4015  0.469
2016 Park TS, Groh EM, Patel K, Kerkar SP, Lee CR, Rosenberg SA. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers. Journal of Immunotherapy (Hagerstown, Md. : 1997). 39: 1-7. PMID 26641256 DOI: 10.1097/CJI.0000000000000101  0.435
2016 Kochenderfer J, Somerville R, Lu T, Shi V, Yang JC, Sherry R, Klebanoff C, Kammula US, Goff SL, Bot A, Rossi J, Sherman M, Perez A, Xue A, Feldman TA, ... Rosenberg SA, et al. Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma. Journal of Clinical Oncology. 34: LBA3010-LBA3010. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba3010  0.464
2016 Lee DW, Stetler-Stevenson M, Yuan CM, Shah NN, Delbrook C, Yates B, Zhang H, Zhang L, Kochenderfer JN, Rosenberg SA, Fry TJ, Stroncek D, Mackall CL. Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation Blood. 128: 218-218. DOI: 10.1182/Blood.V128.22.218.218  0.356
2016 Prickett TD, Crystal J, Gartner J, Yao X, Pasetto A, Gros A, Lu Y, Li YF, El-Gamil M, Rosenberg SA, Robbins P. Abstract PR002: Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-Pr002  0.509
2016 Rosenberg S. Abstract IA01: T cells as a drug for the personalized immunotherapy of cancer Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-Ia01  0.465
2016 Goff S, Feldman S, Somerville R, Rosenberg S. Abstract OT1-01-03: Adoptive cell transfer (ACT) using tumor infiltrating lymphocytes to target neoantigens in patients with metastatic breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Ot1-01-03  0.397
2016 Lu Y, Parker LL, Lu T, Zheng Z, Yao X, Robbins PF, Feldman SA, Bruggen Pvd, Klebanoff CA, Hinrichs CS, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Abstract CT003: A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct003  0.51
2016 Langer T, Lowe E, Perez A, Rosenberg S, Feldman SA, Lu L, Rossi JM, Chang E, Sherman M, Better M, Kochenderfer JN, Bot A. Abstract 2305: Comparative evaluation of peripheral blood T cells and resultant engineered anti-CD19 CAR T cell products from relapsed/refractory non-Hodgkin's lymphoma (NHL) patients Cancer Research. 76: 2305-2305. DOI: 10.1158/1538-7445.Am2016-2305  0.442
2016 Deniger DC, Pasetto A, Prickett TD, Gartner JJ, Bharathan M, Tran E, Robbins PF, Rosenberg SA. 391. Mutated Tumor Neoantigens Are Recognized by Tumor Infiltrating Lymphocytes from Metastatic Ovarian Cancer Molecular Therapy. 24: S155. DOI: 10.1016/S1525-0016(16)33200-2  0.473
2016 Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Parkhurst MR, Matus-Nicodemos R, Douek DC, Gartner J, Trebska-McGowan K, Crystal J, Rosenberg SA. 272. Rapid Identification of Tumor- and Neoantigen-Reactive T-Cell Receptors for Personalized Immunotherapy Molecular Therapy. 24: S108. DOI: 10.1016/S1525-0016(16)33081-7  0.503
2015 Rosenberg SA. CCR 20th Anniversary Commentary: Autologous T Cells-The Ultimate Personalized Drug for the Immunotherapy of Human Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 5409-11. PMID 26672082 DOI: 10.1158/1078-0432.CCR-14-3131  0.413
2015 Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, ... ... Rosenberg SA, et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. The Journal of Clinical Investigation. PMID 26657860 DOI: 10.1172/Jci81217  0.409
2015 Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science (New York, N.Y.). PMID 26516200 DOI: 10.1126/science.aad1253  0.462
2015 Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, Wilmott JS, Gartner JJ, Di Pizio A, Winograd-Katz S, Sindiri S, Rotkopf R, Dutton-Regester K, Johansson P, Pritchard AL, ... ... Rosenberg SA, et al. Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics. PMID 26502337 DOI: 10.1038/Ng.3427  0.365
2015 Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. The Journal of Clinical Investigation. PMID 26389673 DOI: 10.1172/JCI82416  0.487
2015 Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA. Adoptive Cell Therapy-Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. Seminars in Oncology. 42: 626-39. PMID 26320066 DOI: 10.1053/j.seminoncol.2015.05.005  0.518
2015 Beane JD, Lee G, Zheng Z, Mendel M, Abate-Daga D, Bharathan M, Black M, Gandhi N, Yu Z, Chandran S, Giedlin M, Ando D, Miller J, Paschon D, Guschin D, ... ... Rosenberg SA, et al. Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 25939491 DOI: 10.1038/Mt.2015.71  0.341
2015 Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. Journal of Virology. 89: 6685-94. PMID 25878112 DOI: 10.1128/JVI.00474-15  0.398
2015 Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York, N.Y.). 348: 62-8. PMID 25838374 DOI: 10.1126/Science.Aaa4967  0.484
2015 Stevanovi? S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1543-50. PMID 25823737 DOI: 10.1200/Jco.2014.58.9093  0.329
2015 Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, ... ... Rosenberg SA, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2278-88. PMID 25695689 DOI: 10.1158/1078-0432.Ccr-14-2085  0.737
2015 Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, ... Rosenberg SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1019-27. PMID 25538264 DOI: 10.1158/1078-0432.Ccr-14-2708  0.788
2015 Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, ... ... Rosenberg SA, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Research. 75: 296-305. PMID 25432172 DOI: 10.1158/0008-5472.Can-14-2277  0.485
2015 Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, Somerville R, Wunderlich JR, Sherry RM, Yang JC, Rosenberg SA, Kammula US. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 534-43. PMID 25424856 DOI: 10.1158/1078-0432.Ccr-14-2208  0.59
2015 Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 74-82. PMID 25403209 DOI: 10.1200/Jco.2014.57.3329  0.466
2015 Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, ... ... Rosenberg SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (London, England). 385: 517-28. PMID 25319501 DOI: 10.1016/S0140-6736(14)61403-3  0.483
2015 Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, ... ... Rosenberg SA, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 540-9. PMID 25154820 DOI: 10.1200/Jco.2014.56.2025  0.766
2015 Bot A, Kochenderfer J, Mardiros A, Perez A, Navale L, Chang R, Wei-Shen Y, Yoder S, Xiao-Chi J, Rosenberg SA, Go WY, Wiezorek JS, Roberts M, Chang DD. Biomarker analysis of patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells. Journal of Clinical Oncology. 33: 3028-3028. DOI: 10.1200/Jco.2015.33.15_Suppl.3028  0.449
2015 Crystal JS, Prickett TD, Gartner JJ, Parkhurst MR, Lu Y, Gros A, Li Y, Trebska-Mcgowan K, El-Gamil M, Rosenberg SA, Robbins PF. Diversity of mutated antigen recognition by tumor infiltrating lymphocytes from patients with metastatic melanoma Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P9  0.445
2015 Cohen C, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-Mcgowan K, Bliskovsky V, Parkhurst MR, Ankri C, Prickett TD, Crystal J, Li Y, El-Gamil M, Rosenberg SA, Robbins PF. Study and characterization of mutated antigen specific T cells isolated from fresh tumor and peripheral lymphocytes in cancer patients Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P7  0.498
2015 Trebska-Mcgowan K, Bharathan M, Gartner JJ, Prickett TD, Rosenberg SA, Robbins PF. Unique neoantigens expressed by melanomas and common epithelial cancers presented by multiple HLA alleles can be efficiently identified utilizing peptide prediction algorithms Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P57  0.378
2015 Stevanović S, Anna P, Gartner JJ, Tran E, Robbins PF, Rosenberg SA, Hinrichs CS. Adoptively transferred tumor-infiltrating T cells target somatic cancer mutations in a human papillomavirus+ cancer patient with complete tumor regression Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P52  0.457
2015 Bharathan M, Trebska-McGowan K, Anna P, Deniger DC, Hanada K, Gartner JJ, Yang JC, Rosenberg SA, Robbins PF. Tetramer based approach for efficient identification and isolation of neo-antigen specific CD8 T cells from peripheral blood (PBL) of patients with metastatic cancers Journal For Immunotherapy of Cancer. 3: 47. DOI: 10.1186/2051-1426-3-S2-P47  0.475
2015 Anna P, Gros A, Robbins PF, Prickett TD, Deniger DC, Matus-Nicodemus R, Parkhurst MR, Crystal JS, Trebska-Mcgowan K, Rosenberg SA. High frequency CD8+PD-1+ TCR clonotypes isolated from fresh melanomas display anti-tumor activity Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P42  0.48
2015 Parkhurst M, Gros A, Anna P, Tran E, Crystal JS, Prickett T, Robbins P, Rosenberg SA. Use of CD137 up-regulation to identify T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P40  0.483
2015 Assadipour Y, Goff S, Crystal JS, Prickett TD, Gartner JJ, Somerville R, Xu H, Black M, Kriley I, Robbins PF, Rosenberg SA, Feldman S. Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer Journal For Immunotherapy of Cancer. 3: P284. DOI: 10.1186/2051-1426-3-S2-P284  0.371
2015 Hanada K, Chow C, Hoyos RG, Gartner JJ, Prickett TD, Somerville R, Hogan K, Robbins PF, Rosenberg SA, Yang JC. Personalized immunotherapy for non-small cell lung cancer through identification of tumor-specific mutations by next generation sequencing and adoptive transfer of tumor infiltrating lymphocytes that recognize neoantigens Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P20  0.442
2015 Lu Y, Parker L, Lu T, Zheng Z, Yao X, Robbins PF, van der Bruggen P, Klebanoff CA, Hinrichs CS, Goff S, Sherry R, Kammula U, Yang JC, Rosenberg SA. A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P158  0.434
2015 Deniger DC, Bharathan M, Anna P, Tran E, Gartner JJ, Prickett TD, Robbins PF, Rosenberg SA. Identification of mutation-specific tumor infiltrating lymphocytes from metastatic ovarian cancer Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P10  0.402
2015 Prickett TD, Crystal JS, Gartner JJ, Xin Y, Anna P, Gros A, Lu Y, Li Y, El-Gamil M, Rosenberg SA, Robbins P. Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-O4  0.502
2015 Gros A, Tran E, Parkhurst MR, Anna P, Ilyas S, Prickett TD, Gartner JJ, Robbins PF, Crystal JS, Trebska-Mcgowan K, Wudnerlich JR, Yang JC, Rosenberg SA. Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-O2  0.439
2015 Brudno JN, Somerville R, Shi V, Rose JJ, Halverson DC, Fowler DH, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Goy A, Lu TL, Feldman S, Iwamoto A, Kurlander R, Maric I, ... ... Rosenberg SA, et al. Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease Blood. 126: 99-99. DOI: 10.1182/BLOOD.V126.23.99.99  0.391
2015 Lee DW, Stetler-Stevenson M, Yuan CM, Fry TJ, Shah NN, Delbrook C, Yates B, Zhang H, Zhang L, Kochenderfer JN, Rosenberg SA, Stroncek D, Mackall CL. Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia Blood. 126: 684-684. DOI: 10.1182/Blood.V126.23.684.684  0.384
2015 Bot A, Rossi JM, Jiang Y, Navale L, Shen Y, Sherman M, Mardiros A, Yoder SC, Go WY, Rosenberg SA, Wiezorek J, Chang DD, Kochenderfer JN, Roberts MR. Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy Blood. 126: 4426-4426. DOI: 10.1182/Blood.V126.23.4426.4426  0.42
2015 Perez A, Navale L, Rossi JM, Shen Y, Jiang Y, Sherman M, Mardiros A, Yoder SC, Go WY, Rosenberg SA, Wiezorek J, Roberts MR, Chang DD, Kochenderfer JN, Bot A. Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy Blood. 126: 2042-2042. DOI: 10.1182/Blood.V126.23.2042.2042  0.457
2015 Rosenberg SA. Abstract IA19: Curative potential of T-cell immunotherapy for cancer Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Ia19  0.476
2015 Crystal JS, Prickett T, Lu Y, Gartner JJ, Parkhurst M, Gros A, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Abstract LB-221: Diversity of tumor infiltrating lymphocyte recognition of diverse mutated antigens in cutaneous melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-221  0.459
2015 Walia V, Prickett T, Kim J, Gartner JJ, Lin JC, Rosenberg SA, Elble RC, Solomon DA, Waldman T, Samuels Y. Abstract LB-065: Mutational and functional analysis of the tumor suppressor PTPRD in human melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-065  0.338
2015 Beane JD, Lee G, Zheng Z, Gandhi N, Abate-Daga D, Bharathan M, Black M, Mendel M, Yu Z, Kassim SH, Chandran S, Giedlin MA, Ando D, Rebar E, Reik A, ... ... Rosenberg SA, et al. 77. Clinical Scale Zinc Finger Nuclease (ZFN)-Driven Gene-Editing of PD-1 in Tumor Infiltrating Lymphocytes (TIL) for the Potential Treatment of Metastatic Melanoma Molecular Therapy. 23: S33-S34. DOI: 10.1016/S1525-0016(16)33682-6  0.738
2015 Kriley IR, Feldman SA, Tran E, Black M, Xu H, Rosenberg SA, Goff S. Transient retroviral transfection for single patient cancer immunotherapy Journal of the American College of Surgeons. 221: e135. DOI: 10.1016/j.jamcollsurg.2015.08.261  0.31
2014 Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, Rosenberg SA, Morgan RA. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. Journal For Immunotherapy of Cancer. 2: 25. PMID 25197555 DOI: 10.1186/2051-1426-2-25  0.498
2014 Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, ... ... Rosenberg S, et al. T-cell immunotherapy: looking forward. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1564-74. PMID 25186558 DOI: 10.1038/Mt.2014.148  0.38
2014 Walia V, Prickett TD, Kim JS, Gartner JJ, Lin JC, Zhou M, Rosenberg SA, Elble RC, Solomon DA, Waldman T, Samuels Y. Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma. Human Mutation. 35: 1301-10. PMID 25113440 DOI: 10.1002/Humu.22630  0.354
2014 Abate-Daga D, Rosenberg SA, Morgan RA. Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies. Oncoimmunology. 3: e29194. PMID 25083334 DOI: 10.4161/onci.29194  0.469
2014 Feldman SA, Xu H, Black MA, Park TS, Robbins PF, Kochenderfer JN, Morgan RA, Rosenberg SA. Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors. Human Gene Therapy Methods. 25: 253-60. PMID 25072603 DOI: 10.1089/hgtb.2014.071  0.375
2014 Malecek K, Grigoryan A, Zhong S, Gu WJ, Johnson LA, Rosenberg SA, Cardozo T, Krogsgaard M. Specific increase in potency via structure-based design of a TCR. Journal of Immunology (Baltimore, Md. : 1950). 193: 2587-99. PMID 25070852 DOI: 10.4049/Jimmunol.1302344  0.542
2014 Tran E, Rosenberg SA. T-cell therapy against cancer mutations. Oncotarget. 5: 4579-80. PMID 25046408 DOI: 10.18632/Oncotarget.2234  0.473
2014 Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3401-10. PMID 24987109 DOI: 10.1158/1078-0432.CCR-14-0433  0.559
2014 Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y. A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget. 5: 2912-7. PMID 24913145 DOI: 10.18632/Oncotarget.2048  0.318
2014 Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. Journal of Immunology (Baltimore, Md. : 1950). 192: 5451-8. PMID 24907378 DOI: 10.4049/jimmunol.1490019  0.456
2014 Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (New York, N.Y.). 344: 641-5. PMID 24812403 DOI: 10.1126/science.1251102  0.534
2014 Prickett TD, Zerlanko BJ, Hill VK, Gartner JJ, Qutob N, Jiang J, Simaan M, Wunderlich J, Gutkind JS, Rosenberg SA, Samuels Y. Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation. The Journal of Investigative Dermatology. 134: 2390-8. PMID 24739903 DOI: 10.1038/jid.2014.190  0.358
2014 Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Human Gene Therapy. 25: 1003-12. PMID 24694017 DOI: 10.1089/Hum.2013.209  0.507
2014 Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, ... ... Rosenberg SA, et al. Melanoma NOS1 expression promotes dysfunctional IFN signaling. The Journal of Clinical Investigation. 124: 2147-59. PMID 24691438 DOI: 10.1172/Jci69611  0.41
2014 Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. Plos One. 9: e93321. PMID 24681846 DOI: 10.1371/journal.pone.0093321  0.618
2014 Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, ... Rosenberg SA, et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. The Journal of Clinical Investigation. 124: 2246-59. PMID 24667641 DOI: 10.1172/JCI73639  0.528
2014 Bartlett EK, Fetsch PA, Filie AC, Abati A, Steinberg SM, Wunderlich JR, White DE, Stephens DJ, Marincola FM, Rosenberg SA, Kammula US. Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2607-16. PMID 24647571 DOI: 10.1158/1078-0432.CCR-13-2690  0.5
2014 Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA. A novel murine T-cell receptor targeting NY-ESO-1. Journal of Immunotherapy (Hagerstown, Md. : 1997). 37: 135-46. PMID 24598449 DOI: 10.1097/CJI.0000000000000019  0.574
2014 Rosenberg SA. Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Therapy. 21: 45-7. PMID 24535159 DOI: 10.1038/cgt.2014.3  0.531
2014 Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 120: 1426-32. PMID 24474396 DOI: 10.1002/cncr.28547  0.38
2014 Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 972-84. PMID 24352643 DOI: 10.1158/1078-0432.CCR-13-0709  0.414
2014 Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunological Reviews. 257: 56-71. PMID 24329789 DOI: 10.1111/imr.12132  0.606
2014 Aung PP, Liu YC, Ballester LY, Robbins PF, Rosenberg SA, Lee CC. Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Human Pathology. 45: 259-67. PMID 24290058 DOI: 10.1016/j.humpath.2013.05.029  0.493
2014 Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 331-43. PMID 24218514 DOI: 10.1158/1078-0432.CCR-13-1736  0.569
2014 Liu B, Zhong S, Malecek K, Johnson LA, Rosenberg SA, Zhu C, Krogsgaard M. 2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system. European Journal of Immunology. 44: 239-50. PMID 24114747 DOI: 10.1002/Eji.201343774  0.458
2014 Better M, Pugach O, Lu L, Somerville R, Kassim S, Kochenderfer J, Rosenberg SA, Marshall MA, Bot A, Nolop KB, Roberts M, Feldman S. Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR. Journal of Clinical Oncology. 32: 3079-3079. DOI: 10.1200/Jco.2014.32.15_Suppl.3079  0.783
2014 Malecek K, Grigoryan A, Zhong S, Gu WJ, Johnson LA, Rosenberg SA, Cardozo T, Krogsgaard M. Specific increase in T-cell potency via structure-based design of a T-cell receptor for adoptive immunotherapy. Journal of Clinical Oncology. 32: 3063-3063. DOI: 10.1200/Jco.2014.32.15_Suppl.3063  0.392
2014 Crystal JS, Lu YC, Li Y, El-Gamil M, Prickett T, Trebska-McGowan K, Cohen C, Rosenberg SA, Robbins PF. Individual cultures of melanoma tumor infiltrating lymphocytes possess distinct patterns of reactivity with mutated antigens identified by whole exome sequencing of autologous tumors Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P8  0.466
2014 Parkhurst M, Robbins P, Rosenberg S. Isolation of T cell receptors specifically reactive with mutated tumor associated antigens Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P33  0.482
2014 Zhong S, Malecek K, Moogk D, Johnson LA, Yu Z, Grigoryan A, Vega-Saenz de Miera E, Darvishian F, Gu W, McGary K, Huang K, Boyer J, Corse E, Yongzhao S, Rosenberg SA, et al. Engineering the immune response to "self" for effective cancer immunotherapy Journal For Immunotherapy of Cancer. 2: P22. DOI: 10.1186/2051-1426-2-S3-P22  0.371
2014 Tran E, Ahmadzadeh M, Gros A, Turcotte S, Robbins PF, Lu YC, Li Y, Wunderlich J, Gartner J, Hogan K, Yang J, Rosenberg S. Toward cell transfer immunotherapy against patient-specific mutations in gastrointestinal cancers Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-O3  0.446
2014 Kochenderfer JN, Somerville R, Lu L, Iwamoto A, Yang JC, Klebanoff C, Kammula U, Sherry RM, Victoria S, Yuan C, Feldman S, Feldman T, Goy A, Morton KE, Toomey MA, ... Rosenberg SA, et al. Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma Blood. 124: 550-550. DOI: 10.1182/BLOOD.V124.21.550.550  0.44
2014 Lee DW, Stetler-Stevenson M, Sabatino M, Yuan C, Fry TJ, Shah NN, Delbrook C, Yates B, Zhang H, Zhang L, Tschernia N, Cui Y, Feldman S, Kochenderfer JN, Rosenberg SA, et al. Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia Blood. 124: 381-381. DOI: 10.1182/Blood.V124.21.381.381  0.457
2014 Conlon KC, Lugli E, Rosenberg SA, Morris JC, Fleisher T, Welles H, Dubois S, Perera L, Goldman C, Bryant B, Decker J, Shih J, Worthy T, Figg W, Peer C, et al. Abstract 2575: Results from the first-in-human phase I trials of recombinant human Interleukin 15 (rhIL-15) administered as a daily 30 minute intravenous infusion (IVB) for 12 consecutive days or as continuous intravenous infusion (CIV) for 240 hours in patients with refractory metastatic cancers Cancer Research. 74: 2575-2575. DOI: 10.1158/1538-7445.Am2014-2575  0.41
2013 Chen S, Li Y, Depontieu FR, McMiller TL, English AM, Shabanowitz J, Kos F, Sidney J, Sette A, Rosenberg SA, Hunt DF, Mariuzza RA, Topalian SL. Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity. Journal of Immunology (Baltimore, Md. : 1950). 191: 5097-106. PMID 24108701 DOI: 10.4049/Jimmunol.1300467  0.437
2013 Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control : Journal of the Moffitt Cancer Center. 20: 289-97. PMID 24077405 DOI: 10.1177/107327481302000406  0.555
2013 Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, ... Rosenberg SA, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 122: 4129-39. PMID 24055823 DOI: 10.1182/Blood-2013-08-519413  0.78
2013 Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA, Morgan RA. Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4941-50. PMID 24021875 DOI: 10.1158/1078-0432.CCR-13-1253  0.453
2013 Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. Journal of Immunology (Baltimore, Md. : 1950). 191: 2217-25. PMID 23904171 DOI: 10.4049/jimmunol.1300538  0.588
2013 Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A. Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunology, Immunotherapy : Cii. 62: 1563-73. PMID 23903715 DOI: 10.1007/s00262-013-1459-x  0.526
2013 Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood. 122: 1399-410. PMID 23861247 DOI: 10.1182/blood-2013-04-495531  0.481
2013 Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. The Journal of Experimental Medicine. 210: 1125-35. PMID 23712432 DOI: 10.1084/Jem.20130110  0.535
2013 Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. Journal of Immunology (Baltimore, Md. : 1950). 190: 6034-42. PMID 23690473 DOI: 10.4049/jimmunol.1202830  0.557
2013 Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, ... Rosenberg SA, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2152-9. PMID 23650429 DOI: 10.1200/Jco.2012.46.6441  0.503
2013 Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Medicine. 19: 747-52. PMID 23644516 DOI: 10.1038/nm.3161  0.529
2013 Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Research. 73: 3371-80. PMID 23633494 DOI: 10.1158/0008-5472.Can-12-3913  0.555
2013 Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E, Shao Y, Rosenberg SA, Restifo NP, Osman I, Krogsgaard M. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. 110: 6973-8. PMID 23576742 DOI: 10.1073/pnas.1221609110  0.456
2013 Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, Restifo NP. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1369-77. PMID 23568260 DOI: 10.1038/Mt.2013.58  0.467
2013 Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nature Reviews. Clinical Oncology. 10: 267-76. PMID 23546520 DOI: 10.1038/nrclinonc.2013.46  0.459
2013 Malecek K, Zhong S, McGary K, Yu C, Huang K, Johnson LA, Rosenberg SA, Krogsgaard M. Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. Journal of Immunological Methods. 392: 1-11. PMID 23500145 DOI: 10.1016/J.Jim.2013.02.018  0.421
2013 Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, ... ... Rosenberg SA, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 133-51. PMID 23377668 DOI: 10.1097/Cji.0B013E3182829903  0.367
2013 Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunology, Immunotherapy : Cii. 62: 727-36. PMID 23207483 DOI: 10.1007/S00262-012-1378-2  0.431
2013 Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Therapy. 20: 575-80. PMID 22972494 DOI: 10.1038/Gt.2012.75  0.411
2013 Lee DW, Shah N, Stetler-Stevenson M, Sabatino M, Richards K, Delbrook C, Kochenderfer J, Rosenberg SA, Stroncek D, Mackall C, Wayne AS. Autologous-collected anti-CD19 chimeric antigen receptor T cells (19CARTs) for pediatric acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL): Clinical activity and cytokine release without graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Journal of Clinical Oncology. 31: 10008-10008. DOI: 10.1200/JCO.2013.31.15_SUPPL.10008  0.429
2013 Sommariva M, Cheung F, Chen J, Shi R, Zhang L, Morgan R, Bedognetti D, De Giorgi V, Ascierto ML, Rosenberg SA, Marincola FM, Wang E. Genetic inference of immune responsiveness of melanoma cancer patients to TIL therapy Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P63  0.336
2013 Abate-Daga D, Alexander TA, Arons E, Ho M, Robbins PF, Rosenberg SA, Morgan RA. Melanoma-associated B cells are distinct from peripheral blood-derived B cells, and may serve as a source of tumor-targeting antibodies Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P180  0.442
2013 Stroncek DF, Melief CJ, Castiello L, Cesano A, Cheever MA, Civini S, Comin-Anduix B, Gajewski TF, Greenberg PD, Kalinski P, Kaufman HL, Kershaw MH, Khleif SN, Marincola F, Merritt W, ... ... Rosenberg SA, et al. Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-4  0.392
2013 Lee DW, Shah NN, Stetler-Stevenson M, Sabatino M, Delbrook C, Richards K, Kochenderfer JN, Rosenberg SA, Stroncek D, Wayne AS, Mackall CL. Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Blood. 122: 68-68. DOI: 10.1182/blood.v122.21.68.68  0.471
2013 Kochenderfer JN, Dudley ME, Kassim SH, Carpenter RO, Yang JC, Phan GQ, Hughes MS, Sherry RM, Feldman S, Spaner D, Nathan DN, Morton KE, Toomey MA, Rosenberg SA. Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor Blood. 122: 168-168. DOI: 10.1182/Blood.V122.21.168.168  0.773
2013 Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford W, Hakim FT, Halverson D, Fowler DH, Hardy NM, Mato A, Hickstein DD, Gea-Banacloche J, Pavletic SZ, Sportes C, ... Rosenberg SA, et al. Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation Blood. 122: 151-151. DOI: 10.1182/Blood.V122.21.151.151  0.784
2013 Prickett TD, Hill V, Gartner J, Zerlanko B, Jiang J, Samaan M, Wunderlich J, Gutkind S, Rosenberg SA, Samuels Y. Abstract LB-48: Somatic mutation of the NMDAR subunit GRIN2A in malignant melanoma results in loss of tumor suppressor activity. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-48  0.365
2013 Lee DW, Shah N, Stetler-Stevenson M, Sabatino M, Richards K, Delbrook C, Kochenderfer JN, Rosenberg SA, Stroncek D, Mackall CL, Wayne AS. Abstract LB-138: Autologous-collected anti-cd19 chimeric antigen receptor (CAR) T cells for acute lymphocytic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL) in children who have previously undergone allogeneic hematopoietic stem cell transplantation (HSCT). Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-138  0.453
2013 Abate-Daga D, Lagisetty KH, Gattinoni L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. Abstract 3966: Development of a fully-human chimeric antigen receptor against PSCA for the treatment of pancreatic cancer. Cancer Research. 73: 3966-3966. DOI: 10.1158/1538-7445.Am2013-3966  0.394
2012 Zhu S, Van den Eynde BJ, Coulie PG, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 680-8. PMID 23090077 DOI: 10.1097/CJI.0b013e31827338ea  0.436
2012 Gartner JJ, Davis S, Wei X, Lin JC, Trivedi NS, Teer JK, Meltzer PS, Rosenberg SA, Samuels Y. Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. Bmc Genomics. 13: 505. PMID 23006843 DOI: 10.1186/1471-2164-13-505  0.369
2012 Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Science Translational Medicine. 4: 149ra120. PMID 22932225 DOI: 10.1126/Scitranslmed.3004306  0.471
2012 Parker SC, Gartner J, Cardenas-Navia I, Wei X, Ozel Abaan H, Ajay SS, Hansen NF, Song L, Bhanot UK, Killian JK, Gindin Y, Walker RL, Meltzer PS, Mullikin JC, Furey TS, ... ... Rosenberg SA, et al. Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes. Plos Genetics. 8: e1002871. PMID 22912592 DOI: 10.1371/Journal.Pgen.1002871  0.355
2012 Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, ... Rosenberg SA, et al. IRF5 gene polymorphisms in melanoma. Journal of Translational Medicine. 10: 170. PMID 22909381 DOI: 10.1186/1479-5876-10-170  0.336
2012 Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5212-23. PMID 22837179 DOI: 10.1158/1078-0432.CCR-12-1108  0.483
2012 June C, Rosenberg SA, Sadelain M, Weber JS. T-cell therapy at the threshold. Nature Biotechnology. 30: 611-4. PMID 22781680 DOI: 10.1038/Nbt.2305  0.402
2012 Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Human Gene Therapy. 23: 1043-53. PMID 22780919 DOI: 10.1089/hum.2012.041  0.481
2012 Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, ... ... Rosenberg SA, et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology. 1: 409-418. PMID 22754759 DOI: 10.4161/Onci.18851  0.506
2012 Alvarez-Downing MM, Inchauste SM, Dudley ME, White DE, Wunderlich JR, Rosenberg SA, Kammula US. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World Journal of Surgical Oncology. 10: 113. PMID 22726267 DOI: 10.1186/1477-7819-10-113  0.439
2012 Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, King KA, Rudy S, Van Waes C, Morgan RA, Dudley ME, Yang JC, Rosenberg SA, Kim HJ. Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 147: 744-9. PMID 22597578 DOI: 10.1177/0194599812448356  0.375
2012 Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, Dudley ME, Rosenberg SA, Morgan RA. Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 430-9. PMID 22576348 DOI: 10.1097/CJI.0b013e31825898e8  0.422
2012 Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 400-8. PMID 22576345 DOI: 10.1097/CJI.0b013e31825898c5  0.442
2012 Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 119: 5688-96. PMID 22555974 DOI: 10.1182/blood-2011-10-386482  0.431
2012 Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA. A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. Human Gene Therapy Methods. 23: 73-83. PMID 22515320 DOI: 10.1089/Hgtb.2011.199  0.389
2012 Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME. Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. Journal of Translational Medicine. 10: 69. PMID 22475724 DOI: 10.1186/1479-5876-10-69  0.322
2012 Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Science Translational Medicine. 4: 127ps8. PMID 22461638 DOI: 10.1126/scitranslmed.3003634  0.45
2012 Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews. Immunology. 12: 269-81. PMID 22437939 DOI: 10.1038/Nri3191  0.445
2012 Jin J, Sabatino M, Somerville R, Wilson JR, Dudley ME, Stroncek DF, Rosenberg SA. Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 283-92. PMID 22421946 DOI: 10.1097/CJI.0b013e31824e801f  0.357
2012 Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ, Rao M, Restifo NP, ... Rosenberg SA, et al. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. Journal of Translational Medicine. 10: 48. PMID 22420641 DOI: 10.1186/1479-5876-10-48  0.445
2012 Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, Miettinen MM, Lee CC. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 854-8. PMID 22388761 DOI: 10.1038/modpathol.2012.31  0.423
2012 Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 246-9. PMID 22297819 DOI: 10.1038/Mt.2011.288  0.421
2012 Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1672-83. PMID 22291136 DOI: 10.1158/1078-0432.Ccr-11-3050  0.412
2012 Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2039-47. PMID 22271879 DOI: 10.1158/1078-0432.CCR-11-1823  0.352
2012 Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, ... ... Rosenberg SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119: 2709-20. PMID 22160384 DOI: 10.1182/blood-2011-10-384388  0.448
2012 Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, Van Rooij N, Linnemann C, Van Buuren MM, Urbanus JHM, Beltman JB, Straten P, Li YF, Robbins PF, Besser MJ, ... Rosenberg SA, et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients Oncoimmunology. 1: 409-418. DOI: 10.4161/onci.18851  0.369
2012 Turcotte S, Gros A, Wunderlich JR, Hogan K, Wang QJ, Fetsch P, Dudley ME, Rosenberg SA. Study of tumor-infiltrating T-cell reactivity to metastatic gastrointestinal cancers. Journal of Clinical Oncology. 30: e14179-e14179. DOI: 10.1200/jco.2012.30.15_suppl.e14179  0.47
2012 Bedognetti D, Tomei S, Spivey TL, De Giorgi V, Ascierto ML, Wang E, Dudley ME, Uccellini L, Sertoli MR, Marincola F, Rosenberg SA. Evaluation of chemokine-ligand pathways in pretreatment tumor biopsies as predictive biomarker of response to adoptive therapy in metastatic melanoma patients. Journal of Clinical Oncology. 30: 8576-8576. DOI: 10.1200/JCO.2012.30.15_SUPPL.8576  0.389
2012 Lee DW, Stetler-Stevenson M, Sabatino M, Tumaini B, Richards K, Delbrook C, Kochenderfer JN, Rosenberg SA, Stroncek D, Mackall CL, Wayne AS. Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood. 120: 2609-2609. DOI: 10.1182/BLOOD.V120.21.2609.2609  0.454
2012 Samuels Y, Prickett TD, Wei X, Lin JC, Teer JK, Rosenberg SA. Towards Deciphering the Genetic Landscape in Melanoma Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)32625-9  0.35
2011 Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DN, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, ... ... Rosenberg SA, et al. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 620-626. PMID 28160822 DOI: 10.1038/mt.2010.272  0.378
2011 Kochenderfer JN, Rosenberg SA. Chimeric antigen receptor-modified T cells in CLL. The New England Journal of Medicine. 365: 1937-8; author reply. PMID 22087695 DOI: 10.1056/NEJMc1111004#SA2  0.396
2011 Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G, Rosenberg SA, Restifo NP. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. The Journal of Clinical Investigation. 121: 4746-57. PMID 22056381 DOI: 10.1172/Jci58814  0.495
2011 Rosenberg SA, Kochenderfer JN. Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1928-30. PMID 22051601 DOI: 10.1038/mt.2011.223  0.418
2011 Friedman KM, Devillier LE, Feldman SA, Rosenberg SA, Dudley ME. Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 651-61. PMID 21989413 DOI: 10.1097/CJI.0b013e31823284c3  0.504
2011 Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Advances in Surgery. 45: 341-60. PMID 21954698 DOI: 10.1016/j.yasu.2011.04.003  0.47
2011 Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (New York, N.Y.). 333: 1039-43. PMID 21852505 DOI: 10.1126/Science.1203619  0.349
2011 Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6287-97. PMID 21844012 DOI: 10.1158/1078-0432.CCR-11-1347  0.487
2011 Yang S, Liu F, Wang QJ, Rosenberg SA, Morgan RA. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. Plos One. 6: e22560. PMID 21829468 DOI: 10.1371/journal.pone.0022560  0.474
2011 Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nature Reviews. Clinical Oncology. 8: 577-85. PMID 21808266 DOI: 10.1038/nrclinonc.2011.116  0.454
2011 Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5343-52. PMID 21737507 DOI: 10.1158/1078-0432.Ccr-11-0503  0.506
2011 Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends in Biotechnology. 29: 550-7. PMID 21663987 DOI: 10.1016/j.tibtech.2011.04.009  0.487
2011 Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, ... ... Rosenberg SA, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England Journal of Medicine. 364: 2119-27. PMID 21631324 DOI: 10.1056/Nejmoa1012863  0.314
2011 Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J, Strome SE. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Research. 71: 3175-81. PMID 21531763 DOI: 10.1158/0008-5472.Can-10-4035  0.422
2011 Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nature Genetics. 43: 442-6. PMID 21499247 DOI: 10.1038/Ng.810  0.312
2011 Huang J, Wang QJ, Yang S, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 327-35. PMID 21499130 DOI: 10.1097/CJI.0b013e318216983d  0.419
2011 Langan RC, Prieto PA, Sherry RM, Zlott D, Wunderlich J, Csako G, Costello R, White DE, Rosenberg SA, Yang JC. Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 397-402. PMID 21499128 DOI: 10.1097/CJI.0b013e3182187508  0.305
2011 Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 343-52. PMID 21499127 DOI: 10.1097/Cji.0B013E3182187600  0.352
2011 Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4550-7. PMID 21498393 DOI: 10.1158/1078-0432.Ccr-11-0116  0.46
2011 Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. CARs on track in the clinic. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 432-8. PMID 21358705 DOI: 10.1038/Mt.2011.1  0.398
2011 Yang S, Gattinoni L, Luca G, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunology, Immunotherapy : Cii. 60: 739-49. PMID 21305379 DOI: 10.1007/S00262-011-0977-7  0.475
2011 Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 751-9. PMID 21285960 DOI: 10.1038/Mt.2010.313  0.424
2011 Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, ... Rosenberg SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 917-24. PMID 21282551 DOI: 10.1200/Jco.2010.32.2537  0.534
2011 Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, ... Rosenberg SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 620-6. PMID 21157437 DOI: 10.1038/Mt.2010.272  0.481
2011 Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. Journal of Immunology (Baltimore, Md. : 1950). 186: 685-96. PMID 21149604 DOI: 10.4049/Jimmunol.1001775  0.376
2011 Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, ... Rosenberg SA, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 117: 808-14. PMID 20971955 DOI: 10.1182/Blood-2010-05-286286  0.435
2011 Kochenderfer JN, Dudley ME, Feldman S, Wilson WH, Spaner D, Devillier L, Carpenter R, Nathan DN, Maric I, Morgan RA, Rosenberg SA. B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor Blood. 118: 167-167. DOI: 10.1182/Blood.V118.21.167.167  0.486
2011 Prickett TD, Wei X, Viloria CG, Molinolo A, Lin JC, Cruz P, Rosenberg SA, Davies MA, Gershenwald JE, López-Otin C, Samuels Y. Abstract 4970: Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma Cancer Research. 71: 4970-4970. DOI: 10.1158/1538-7445.Am2011-4970  0.329
2011 Ertl HCJ, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J. Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a Recombinant DNA Advisory Committee symposium held June 15, 2010 (Cancer Research (2011) 71, (3175-3181)) Cancer Research. 71: 4325. DOI: 10.1158/0008-5472.Can-11-1396  0.372
2011 Scott CD, Klebanoff CA, Roychoudhuri R, Kerkar SP, Borman ZA, Rosenberg SA, Restifo NP. Activation of naïve CD8+ T cells by memory cells impairs antitumor immunity in adoptive cell transfer Journal of the American College of Surgeons. 213: S104-S105. DOI: 10.1016/J.Jamcollsurg.2011.06.233  0.393
2011 Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. Erratum to: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells Cancer Immunology, Immunotherapy. 60: 751-751. DOI: 10.1007/S00262-011-0994-6  0.473
2010 Davis JL, Theoret MR, Zheng Z, Lamers CH, Rosenberg SA, Morgan RA. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5852-61. PMID 21138872 DOI: 10.1158/1078-0432.CCR-10-1280  0.472
2010 Wei X, Prickett TD, Viloria CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, Rosenberg SA, Davies MA, Gershenwald JE, López-Otín C, Samuels Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Molecular Cancer Research : McR. 8: 1513-25. PMID 21047771 DOI: 10.1158/1541-7786.Mcr-10-0262  0.321
2010 Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. The Journal of Clinical Investigation. 120: 3953-68. PMID 20978347 DOI: 10.1172/Jci43490  0.484
2010 Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 956-64. PMID 20948441 DOI: 10.1097/CJI.0b013e3181fad2b0  0.406
2010 Rosenberg SA. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1744-5. PMID 20885433 DOI: 10.1038/mt.2010.195  0.477
2010 Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 828-33. PMID 20842054 DOI: 10.1097/CJI.0b013e3181eec14c  0.364
2010 Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 840-7. PMID 20842052 DOI: 10.1097/CJI.0b013e3181f05b91  0.432
2010 Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, Quezado M, Rosenberg SA, Royal RE. Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines. Cancer Immunology, Immunotherapy : Cii. 59: 1757-69. PMID 20734041 DOI: 10.1007/s00262-010-0897-y  0.417
2010 Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4892-8. PMID 20719934 DOI: 10.1158/1078-0432.CCR-10-1507  0.34
2010 Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer Journal (Sudbury, Mass.). 16: 336-41. PMID 20693844 DOI: 10.1097/PPO.0b013e3181eb3879  0.484
2010 Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 116: 4099-102. PMID 20668228 DOI: 10.1182/blood-2010-04-281931  0.457
2010 Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, ... ... Rosenberg SA, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6122-31. PMID 20668005 DOI: 10.1158/1078-0432.Ccr-10-1297  0.449
2010 Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 672-83. PMID 20664359 DOI: 10.1097/CJI.0b013e3181e475cd  0.461
2010 Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Research. 70: 6725-34. PMID 20647327 DOI: 10.1158/0008-5472.Can-10-0735  0.477
2010 Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 116: 3875-86. PMID 20631379 DOI: 10.1182/Blood-2010-01-265041  0.422
2010 Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Research. 70: 6171-80. PMID 20631075 DOI: 10.1158/0008-5472.Can-10-0153  0.427
2010 Goff SL, Johnson LA, Black MA, Xu H, Zheng Z, Cohen CJ, Morgan RA, Rosenberg SA, Feldman SA. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunology, Immunotherapy : Cii. 59: 1551-60. PMID 20628878 DOI: 10.1007/s00262-010-0882-5  0.446
2010 Klapper JA, Davis JL, Ripley RT, Smith FO, Nguyen DM, Kwong KF, Mercedes L, Kemp CD, Mathur A, White DE, Dudley ME, Wunderlich JR, Rosenberg SA, Schrump DS. Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience. The Journal of Thoracic and Cardiovascular Surgery. 140: 1276-82. PMID 20584535 DOI: 10.1016/j.jtcvs.2010.05.020  0.396
2010 Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM. Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 626-9. PMID 20551834 DOI: 10.1097/Cji.0B013E3181Dac9De  0.367
2010 Yang S, Dudley ME, Rosenberg SA, Morgan RA. A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 648-58. PMID 20551831 DOI: 10.1097/CJI.0b013e3181e311cb  0.422
2010 Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clinical Immunology (Orlando, Fla.). 136: 338-47. PMID 20547105 DOI: 10.1016/j.clim.2010.04.013  0.441
2010 Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 547-56. PMID 20463593 DOI: 10.1097/CJI.0b013e3181d367bd  0.411
2010 Davis JL, Ripley RT, Frankel TL, Maric I, Lozier JN, Rosenberg SA. Paraneoplastic granulocytosis in metastatic melanoma. Melanoma Research. 20: 326-9. PMID 20440226 DOI: 10.1097/CMR.0b013e328339da1e  0.36
2010 Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA, Morgan RA. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. Journal of Immunology (Baltimore, Md. : 1950). 184: 5988-98. PMID 20427771 DOI: 10.4049/Jimmunol.1000189  0.443
2010 Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Research. 70: 3027-33. PMID 20395199 DOI: 10.1158/0008-5472.Can-09-2824  0.487
2010 Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 843-51. PMID 20179677 DOI: 10.1038/mt.2010.24  0.488
2010 Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 1-7. PMID 19952961 DOI: 10.1097/Cji.0B013E3181B88Ffc  0.474
2010 Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I. Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Annals of Surgical Oncology. 17: 163-70. PMID 19777192 DOI: 10.1245/s10434-009-0677-0  0.357
2010 Kochenderfer JN, Dudley ME, Stetler-Stevenson M, Wilson WH, Janik JE, Nathan DN, Maric I, Raffeld M, Feldman SA, Morgan RA, Rosenberg SA. A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells Blood. 116: 2865-2865. DOI: 10.1182/BLOOD.V116.21.2865.2865  0.481
2010 Paul RF, Morgan RA, Feldman SA, Yang JC, Dudley ME, Li YF, El-Gamil M, Schwarz SL, Rosenberg SA. Abstract LB-175: Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-175  0.359
2009 Kohrt H, Johannsen A, Hoppe R, Horning SJ, Rosenberg SA, Advani R, Lee PP. Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. Oncology Research. 18: 287-92. PMID 20225766 DOI: 10.3727/096504009X12596189659169  0.302
2009 Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. Journal of Immunology (Baltimore, Md. : 1950). 183: 5563-74. PMID 19843940 DOI: 10.4049/Jimmunol.0900447  0.405
2009 Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, ... Rosenberg SA, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 106: 17469-74. PMID 19805141 DOI: 10.1073/Pnas.0907448106  0.434
2009 Smith FO, Klapper JA, Wunderlich JR, Rosenberg SA, Dudley ME. Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 870-4. PMID 19752747 DOI: 10.1097/CJI.0b013e3181b36b69  0.459
2009 Goff SL, Robbins PF, El-Gamil M, Rosenberg SA. No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 884-5. PMID 19752745 DOI: 10.1097/CJI.0b013e3181affbf0  0.33
2009 Burns WR, Zheng Z, Rosenberg SA, Morgan RA. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood. 114: 2888-99. PMID 19589923 DOI: 10.1182/blood-2009-01-199216  0.462
2009 Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 689-702. PMID 19561539 DOI: 10.1097/CJI.0b013e3181ac6138  0.463
2009 Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Therapy. 16: 1042-9. PMID 19494842 DOI: 10.1038/gt.2009.54  0.412
2009 Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, ... Rosenberg SA, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 114: 535-46. PMID 19451549 DOI: 10.1182/Blood-2009-03-211714  0.48
2009 Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 114: 1537-44. PMID 19423728 DOI: 10.1182/blood-2008-12-195792  0.409
2009 Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 116: 981-989.e1. PMID 19410956 DOI: 10.1016/J.Ophtha.2008.12.004  0.422
2009 Klapper JA, Thomasian AA, Smith DM, Gorgas GC, Wunderlich JR, Smith FO, Hampson BS, Rosenberg SA, Dudley ME. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. Journal of Immunological Methods. 345: 90-9. PMID 19389403 DOI: 10.1016/j.jim.2009.04.009  0.456
2009 Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Current Opinion in Immunology. 21: 233-40. PMID 19304471 DOI: 10.1016/j.coi.2009.03.002  0.499
2009 Jones S, Peng PD, Yang S, Hsu C, Cohen CJ, Zhao Y, Abad J, Zheng Z, Rosenberg SA, Morgan RA. Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Human Gene Therapy. 20: 630-40. PMID 19265475 DOI: 10.1089/hum.2008.048  0.385
2009 Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, Rosenberg SA. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 169-80. PMID 19118044 DOI: 10.1158/1078-0432.CCR-08-1638  0.45
2009 Wargo JA, Robbins PF, Li Y, Zhao Y, El-Gamil M, Caragacianu D, Zheng Z, Hong JA, Downey S, Schrump DS, Rosenberg SA, Morgan RA. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunology, Immunotherapy : Cii. 58: 383-94. PMID 18677478 DOI: 10.1007/s00262-008-0562-x  0.44
2009 Frankel T, Rosenberg S, Morgan R. 185. Cloning and Modification of a T-Cell Receptor Gene Targeting Tyrosinase Confers Peptide and HLA Specific Reactivity to Transduced Peripheral Blood Lymphocytes Journal of Surgical Research. 151: 256-257. DOI: 10.1016/J.JSS.2008.11.224  0.377
2008 Theoret MR, Cohen CJ, Dudley ME, Morgan RA, Rosenberg SA. In vitro and in vivo studies of human lymphocytes genetically engineered to express T cell receptors that recognize a p53 antigenic epitope. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3032. PMID 27947569 DOI: 10.1200/jco.2008.26.15_suppl.3032  0.503
2008 Theoret MR, Cohen CJ, Nahvi AV, Ngo LT, Suri KB, Powell DJ, Dudley ME, Morgan RA, Rosenberg SA. Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Human Gene Therapy. 19: 1219-32. PMID 19848582 DOI: 10.1089/HUM.2008.083  0.467
2008 Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y, Waldman T. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Research. 68: 10300-6. PMID 19074898 DOI: 10.1158/0008-5472.Can-08-3272  0.34
2008 Yang S, Rosenberg SA, Morgan RA. Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 830-9. PMID 18833004 DOI: 10.1097/CJI.0b013e31818817c5  0.387
2008 Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ, Wunderlich JR, Merino MJ, Rosenberg SA. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood. 112: 4953-60. PMID 18820132 DOI: 10.1182/blood-2008-06-163048  0.492
2008 Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, ... ... Rosenberg SA, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5233-9. PMID 18809613 DOI: 10.1200/Jco.2008.16.5449  0.391
2008 Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood. 112: 4746-54. PMID 18799724 DOI: 10.1182/Blood-2008-07-169797  0.471
2008 Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 742-51. PMID 18779745 DOI: 10.1097/CJI.0b013e31818403d5  0.446
2008 Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5610-8. PMID 18765555 DOI: 10.1158/1078-0432.Ccr-08-0116  0.317
2008 Rosenberg SA. Overcoming obstacles to the effective immunotherapy of human cancer. Proceedings of the National Academy of Sciences of the United States of America. 105: 12643-4. PMID 18753635 DOI: 10.1073/pnas.0806877105  0.444
2008 Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proceedings of the National Academy of Sciences of the United States of America. 105: 8061-6. PMID 18523011 DOI: 10.1073/Pnas.0710929105  0.458
2008 Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, Yu Z, Zheng Z, Jones S, Restifo NP, Rosenberg SA, Morgan RA. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Therapy. 15: 1411-23. PMID 18496571 DOI: 10.1038/Gt.2008.90  0.397
2008 Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 113: 293-301. PMID 18457330 DOI: 10.1002/cncr.23552  0.374
2008 Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, Zheng Z, Shelton TE, Matsuda K, Robbins PF, Morgan RA, Rosenberg SA. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Human Gene Therapy. 19: 496-510. PMID 18444786 DOI: 10.1089/hum.2007.0171  0.409
2008 Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. Journal of Immunology (Baltimore, Md. : 1950). 180: 6116-31. PMID 18424733 DOI: 10.4049/Jimmunol.180.9.6116  0.422
2008 Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews. Cancer. 8: 299-308. PMID 18354418 DOI: 10.1038/Nrc2355  0.403
2008 Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 111: 5326-33. PMID 18276844 DOI: 10.1182/Blood-2007-09-113050  0.396
2008 Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA. T-cell receptor gene therapy of established tumors in a murine melanoma model. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 1-6. PMID 18157006 DOI: 10.1097/Cji.0B013E31815C193F  0.5
2008 Ahmadzadeh M, Rosenberg S. Su.65. PD-1 is Expressed by Human Tumor Infiltrating T Cells in Tumors but not in Peripheral Blood and its Expression Correlates with Impaired Effector Function Clinical Immunology. 127: S145. DOI: 10.1016/j.clim.2008.03.416  0.403
2008 Ahmadzadeh M, Felipe-Silva A, Merino M, Rosenberg S. OR.86. Accumulation of Tumor Infiltrating FOXP3+ CD4+ Regulatory T Cells in Tumors and Not in Peripheral Blood in Patients with Melanoma Clinical Immunology. 127: S35. DOI: 10.1016/j.clim.2008.03.093  0.464
2007 Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Seminars in Oncology. 34: 524-31. PMID 18083376 DOI: 10.1053/j.seminoncol.2007.09.002  0.49
2007 Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 825-30. PMID 18049334 DOI: 10.1097/CJI.0b013e318156e47e  0.453
2007 Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6681-8. PMID 17982122 DOI: 10.1158/1078-0432.CCR-07-0187  0.398
2007 Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LY, Li Y, Molloy PE, Dunn SM, Jakobsen BK, Rosenberg SA, Morgan RA. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. Journal of Immunology (Baltimore, Md. : 1950). 179: 5845-54. PMID 17947658 DOI: 10.4049/jimmunol.179.9.5845  0.435
2007 Powell DJ, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, White DE, Mavroukakis S, Kreitman RJ, Rosenberg SA, Pastan I. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. Journal of Immunology (Baltimore, Md. : 1950). 179: 4919-28. PMID 17878392 DOI: 10.4049/Jimmunol.179.7.4919  0.429
2007 Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP. Toll-like receptors in tumor immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5280-9. PMID 17875756 DOI: 10.1158/1078-0432.Ccr-07-1378  0.472
2007 Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. The Journal of Clinical Investigation. 117: 2197-204. PMID 17657310 DOI: 10.1172/Jci32205  0.422
2007 Powell DJ, de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA. Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 438-47. PMID 17457218 DOI: 10.1097/CJI.0b013e3180600ff9  0.481
2007 Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Research. 67: 3898-903. PMID 17440104 DOI: 10.1158/0008-5472.CAN-06-3986  0.408
2007 Ahmadzadeh M, Antony PA, Rosenberg SA. IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 294-302. PMID 17414320 DOI: 10.1097/CJI.0b013e3180336787  0.422
2007 Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Research. 67: 2425-9. PMID 17363559 DOI: 10.1158/0008-5472.Can-06-3977  0.505
2007 Hsu C, Jones SA, Cohen CJ, Zheng Z, Kerstann K, Zhou J, Robbins PF, Peng PD, Shen X, Gomes TJ, Dunbar CE, Munroe DJ, Stewart C, Cornetta K, Wangsa D, ... ... Rosenberg SA, et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood. 109: 5168-77. PMID 17353346 DOI: 10.1182/Blood-2006-06-029173  0.458
2007 Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. The Journal of Clinical Investigation. 117: 492-501. PMID 17273561 DOI: 10.1172/Jci30414  0.48
2007 Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ, Rosenberg SA, Hodes RJ. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 123-9. PMID 17198091 DOI: 10.1097/01.cji.0000211321.07654.b8  0.424
2007 Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling Journal of Clinical Investigation. 117: 3140-3140. DOI: 10.1172/Jci32205C1  0.396
2006 Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP. Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nature Clinical Practice. Oncology. 3: 668-81. PMID 17139318 DOI: 10.1038/Ncponc0666  0.445
2006 Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, Parkhurst MR. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 616-27. PMID 17063124 DOI: 10.1097/01.cji.0000211312.36363.56  0.446
2006 Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6106-15. PMID 17062687 DOI: 10.1158/1078-0432.Ccr-06-1183  0.381
2006 Johnson LA, Heemskerk B, Powell DJ, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 177: 6548-59. PMID 17056587 DOI: 10.4049/Jimmunol.177.9.6548  0.506
2006 Powell DJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. Journal of Immunology (Baltimore, Md. : 1950). 177: 6527-39. PMID 17056585 DOI: 10.4049/Jimmunol.177.9.6527  0.468
2006 Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5801-8. PMID 17020987 DOI: 10.1158/1078-0432.Ccr-05-2421  0.488
2006 Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Research. 66: 8878-86. PMID 16951205 DOI: 10.1158/0008-5472.CAN-06-1450  0.425
2006 Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (New York, N.Y.). 314: 126-9. PMID 16946036 DOI: 10.1126/Science.1129003  0.487
2006 Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA, Restifo NP. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood. 108: 3818-23. PMID 16882704 DOI: 10.1182/Blood-2006-07-034066  0.44
2006 Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 455-63. PMID 16799341 DOI: 10.1097/01.cji.0000208259.73167.58  0.38
2006 Zhao Y, Zheng Z, Khong HT, Rosenberg SA, Morgan RA. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 398-406. PMID 16799335 DOI: 10.1097/01.cji.0000203082.20365.7f  0.462
2006 Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 176: 7726-35. PMID 16751420 DOI: 10.4049/Jimmunol.176.12.7726  0.393
2006 Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2283-9. PMID 16710025 DOI: 10.1200/JCO.2005.04.5716  0.304
2006 Shafer-Weaver K, Rosenberg S, Strobl S, Gregory Alvord W, Baseler M, Malyguine A. Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 328-35. PMID 16699376 DOI: 10.1097/01.cji.0000203079.35612.c8  0.385
2006 Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 313-9. PMID 16699374 DOI: 10.1097/01.cji.0000210386.55951.c2  0.375
2006 Liu S, Riley J, Rosenberg S, Parkhurst M. Comparison of common γ-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy Journal of Immunotherapy. 29: 284-293. PMID 16699371 DOI: 10.1097/01.cji.0000190168.53793.6b  0.437
2006 Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, ... Rosenberg SA, et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2526-37. PMID 16638862 DOI: 10.1158/1078-0432.Ccr-05-2061  0.32
2006 Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nature Reviews. Immunology. 6: 383-93. PMID 16622476 DOI: 10.1038/Nri1842  0.408
2006 Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE. Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 224-31. PMID 16531823 DOI: 10.1097/01.Cji.0000190399.98802.10  0.307
2006 Attia P, Powell DJ, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 208-14. PMID 16531821 DOI: 10.1097/01.cji.0000187959.45803.0c  0.446
2006 Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA, Hwang ST. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Archives of Dermatology. 142: 166-72. PMID 16490844 DOI: 10.1001/archderm.142.2.166  0.377
2006 Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 107: 2409-14. PMID 16304057 DOI: 10.1182/blood-2005-06-2399  0.412
2006 Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Molecular Therapy : the Journal of the American Society of Gene Therapy. 13: 151-9. PMID 16140584 DOI: 10.1016/J.Ymthe.2005.07.688  0.438
2006 Jones S, Hsu C, Morgan R, Rosenberg S. 767. Genetic Engineering of an Immortal Human CD8+ T Cell Line Molecular Therapy. 13: S297. DOI: 10.1016/j.ymthe.2006.08.852  0.507
2006 Zhao Y, Zheng Z, Cohen CJ, Rosenberg SA, Morgan RA. 454. Recognition of Tumor Antigens by In Vitro Developed T Cells from Hematopoietic Stem Cells Retrovirally Transduced with TCR Genes Molecular Therapy. 13: S175. DOI: 10.1016/j.ymthe.2006.08.522  0.467
2006 Hsu C, Rosenberg S, Morgan R. 979. Clonal Expansion of a CD8+ T Cell Clone after Retroviral Transduction of Mature T Lymphocytes with the IL-15 Gene Molecular Therapy. 13: S376-S377. DOI: 10.1016/j.ymthe.2006.08.1072  0.442
2006 Rosenberg SA, Restifo NP. Response to comment on "tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma" [2] Journal of Immunology. 176: 4511-4512.  0.372
2005 Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. Journal of Immunology (Baltimore, Md. : 1950). 175: 7746-54. PMID 16301685 DOI: 10.4049/Jimmunol.175.11.7746  0.406
2005 Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. Journal of Immunology (Baltimore, Md. : 1950). 175: 7226-34. PMID 16301627 DOI: 10.4049/Jimmunol.175.11.7226  0.361
2005 Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Annals of Surgical Oncology. 12: 1005-16. PMID 16283570 DOI: 10.1245/ASO.2005.03.536  0.5
2005 Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. Journal of Immunology (Baltimore, Md. : 1950). 175: 7046-52. PMID 16272366 DOI: 10.4049/Jimmunol.175.10.7046  0.47
2005 Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. Journal of Immunology (Baltimore, Md. : 1950). 175: 6169-76. PMID 16237114 DOI: 10.4049/Jimmunol.175.9.6169  0.481
2005 Cohen CJ, Zheng Z, Bray R, Zhao Y, Sherman LA, Rosenberg SA, Morgan RA. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. Journal of Immunology (Baltimore, Md. : 1950). 175: 5799-808. PMID 16237072 DOI: 10.4049/Jimmunol.175.9.5799  0.438
2005 Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 593-8. PMID 16224277 DOI: 10.1097/01.Cji.0000178913.41256.06  0.452
2005 Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 582-92. PMID 16224276 DOI: 10.1097/01.Cji.0000175468.19742.10  0.458
2005 Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 517-24. PMID 16224268 DOI: 10.1097/01.Cji.0000177999.95831.7B  0.429
2005 Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. The Journal of Experimental Medicine. 202: 907-12. PMID 16203864 DOI: 10.1084/Jem.20050732  0.483
2005 Aisner DL, Maker A, Rosenberg SA, Berman DM. Loss of S100 antigenicity in metastatic melanoma. Human Pathology. 36: 1016-9. PMID 16153466 DOI: 10.1016/j.humpath.2005.07.010  0.33
2005 Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, ... ... Rosenberg SA, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6043-53. PMID 16087944 DOI: 10.1200/Jco.2005.06.205  0.454
2005 Powell DJ, Parker LL, Rosenberg SA. Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 403-11. PMID 16000960 DOI: 10.1097/01.Cji.0000170363.22585.5A  0.387
2005 Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America. 102: 9571-6. PMID 15980149 DOI: 10.1073/Pnas.0503726102  0.474
2005 Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. The Journal of Clinical Investigation. 115: 1616-26. PMID 15931392 DOI: 10.1172/Jci24480  0.493
2005 Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y, Wunderlich J, Hawley RG, Moayeri M, Rosenberg SA, Morgan RA. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Human Gene Therapy. 16: 457-72. PMID 15871677 DOI: 10.1089/hum.2005.16.457  0.506
2005 Rosenberg SA. The emergence of modern cancer immunotherapy. Annals of Surgical Oncology. 12: 344-6. PMID 15843873 DOI: 10.1245/ASO.2005.01.904  0.455
2005 Ahmadzadeh M, Rosenberg SA. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. Journal of Immunology (Baltimore, Md. : 1950). 174: 5215-23. PMID 15843517 DOI: 10.4049/Jimmunol.174.9.5215  0.392
2005 Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 258-67. PMID 15838383 DOI: 10.1097/01.Cji.0000158855.92792.7A  0.467
2005 Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, ... ... Rosenberg SA, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2346-57. PMID 15800326 DOI: 10.1200/Jco.2005.00.240  0.419
2005 Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. Journal of Immunology (Baltimore, Md. : 1950). 174: 4415-23. PMID 15778407 DOI: 10.4049/Jimmunol.174.7.4415  0.482
2005 Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Research. 65: 2001-8. PMID 15753400 DOI: 10.1158/0008-5472.Can-04-2006  0.497
2005 Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. Journal of Immunology (Baltimore, Md. : 1950). 174: 2591-601. PMID 15728465 DOI: 10.4049/Jimmunol.174.5.2591  0.442
2005 Restifo NP, Rosenberg SA. Use of standard criteria for assessment of cancer vaccines. The Lancet. Oncology. 6: 3-4. PMID 15629270 DOI: 10.1016/S1470-2045(04)01693-6  0.333
2005 Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 53-62. PMID 15614045 DOI: 10.1097/00002371-200501000-00007  0.511
2005 Powell DJ, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 105: 241-50. PMID 15345595 DOI: 10.1182/blood-2004-06-2482  0.49
2005 Wrzesinski C, Gattinoni L, Palmer DC, Paulos CM, Yu Z, Rosenberg SA, Restifo NP. Hematopoietic Stem Cell Transplant With Lymphodepletion Augments T Cell-based Adoptive Immunotherapy Journal of Immunotherapy. 28: 619. DOI: 10.1097/01.Cji.0000190968.11149.79  0.343
2005 Maker AV, Attia P, Rosenberg S. Cellular mechanisms of anti-tumor responses in patients treated with CTLA-4 blockade Journal of the American College of Surgeons. 201: S86-S87. DOI: 10.1016/j.jamcollsurg.2005.06.204  0.379
2004 Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. Journal of Immunology (Baltimore, Md. : 1950). 173: 7622-9. PMID 15585890 DOI: 10.4049/Jimmunol.173.12.7622  0.498
2004 Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Rosenberg SA. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. Journal of Immunology (Baltimore, Md. : 1950). 173: 7125-30. PMID 15585832 DOI: 10.4049/Jimmunol.173.12.7125  0.496
2004 Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 478-9. PMID 15534492 DOI: 10.1097/00002371-200411000-00008  0.469
2004 Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 472-7. PMID 15534491 DOI: 10.1097/00002371-200411000-00007  0.345
2004 Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 101: 14639-45. PMID 15381769 DOI: 10.1073/pnas.0405730101  0.497
2004 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Medicine. 10: 909-15. PMID 15340416 DOI: 10.1038/Nm1100  0.32
2004 Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4688-98. PMID 15269141 DOI: 10.1158/1078-0432.CCR-04-0325  0.437
2004 Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 259-64. PMID 15235386 DOI: 10.1097/00002371-200407000-00001  0.341
2004 Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. Journal of Leukocyte Biology. 76: 333-7. PMID 15155774 DOI: 10.1189/Jlb.0304120  0.499
2004 Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. Journal of Immunology (Baltimore, Md. : 1950). 172: 6057-64. PMID 15128789 DOI: 10.4049/Jimmunol.172.10.6057  0.466
2004 Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. Journal of the American College of Surgeons. 198: 685-96. PMID 15110801 DOI: 10.1016/j.jamcollsurg.2004.01.025  0.391
2004 Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 184-90. PMID 15076135 DOI: 10.1097/00002371-200405000-00002  0.48
2004 Rosenberg SA. Shedding light on immunotherapy for cancer. The New England Journal of Medicine. 350: 1461-3. PMID 15070799 DOI: 10.1056/NEJMcibr045001  0.41
2004 Parkhurst MR, Riley JP, Robbins PF, Rosenberg SA. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 79-91. PMID 14770079 DOI: 10.1097/00002371-200403000-00001  0.462
2004 Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America. 101: 1969-74. PMID 14762166 DOI: 10.1073/Pnas.0307298101  0.437
2004 Powell DJ, Rosenberg SA. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 36-47. PMID 14676632 DOI: 10.1097/00002371-200401000-00004  0.451
2004 Liu K, Rosenberg SA. Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 190-201. PMID 12806273 DOI: 10.1097/00002371-200305000-00003  0.421
2004 Finkelstein S, Klebanoff C, Antony P, Gattinoni L, Heimann D, Hinrichs C, Hwang L, Palmer D, Spiess P, Rosenberg S, Restifo N. IFN-gamma production by adoptively transferred CD8+ T lymphocytes and host cells contributes to successful tumor immunotherapy Journal of the American College of Surgeons. 199: 90-91. DOI: 10.1016/J.Jamcollsurg.2004.05.197  0.436
2004 Finkelstein SE, Klebanoff CA, Antony PA, Hwang LN, Heimann DM, Spiess PJ, Surman DR, Palmer DC, Rosenberg SA, Restifo NP. IL-7 and IL-15 can trigger cancer regression after adoptive transfer of CD8+T lymphocytes Annals of Surgical Oncology. 11: S70-S70. DOI: 10.1007/BF02524031  0.35
2003 Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Research. 63: 6735-43. PMID 14583468  0.529
2003 Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 385-93. PMID 12973027 DOI: 10.1097/00002371-200309000-00001  0.49
2003 Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. Journal of Immunology (Baltimore, Md. : 1950). 171: 3287-95. PMID 12960359 DOI: 10.4049/Jimmunol.171.6.3287  0.439
2003 Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nature Reviews. Cancer. 3: 666-75. PMID 12951585 DOI: 10.1038/nrc1167  0.426
2003 Nagorsen D, Panelli M, Dudley ME, Finkelstein SE, Rosenberg SA, Marincola FM. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Gene Therapy. 10: 1754-65. PMID 12939642 DOI: 10.1038/sj.gt.3302066  0.312
2003 Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, ... Rosenberg SA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. The Journal of Experimental Medicine. 198: 569-80. PMID 12925674 DOI: 10.1084/Jem.20030590  0.486
2003 Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 3127-32. PMID 12915604 DOI: 10.1200/JCO.2003.02.122  0.324
2003 Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 349-56. PMID 12843797 DOI: 10.1097/00002371-200307000-00007  0.415
2003 Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 332-42. PMID 12843795 DOI: 10.1097/00002371-200307000-00005  0.437
2003 Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, ... Rosenberg SA, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America. 100: 8372-7. PMID 12826605 DOI: 10.1073/Pnas.1533209100  0.467
2003 Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Human Gene Therapy. 14: 709-14. PMID 12804135 DOI: 10.1089/104303403765255110  0.397
2003 Riley JP, Rosenberg SA, Parkhurst MR. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities Journal of Immunological Methods. 276: 103-119. PMID 12738363 DOI: 10.1016/S0022-1759(03)00078-4  0.425
2003 Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules Journal of Immunology. 170: 5317-5325. PMID 12734382 DOI: 10.4049/jimmunol.170.10.5317  0.436
2003 Heimann DM, Rosenberg SA. Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 179-80. PMID 12616110 DOI: 10.1097/00002371-200303000-00011  0.376
2003 Attia P, Phan GQ, Duray PH, Rosenberg SA. Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: case report and review. American Journal of Clinical Oncology. 26: 42-5. PMID 12576923 DOI: 10.1097/00000421-200302000-00009  0.334
2003 Touloukian CE, Leitner WW, Schnur RE, Robbins PF, Li Y, Southwood S, Sette A, Rosenberg SA, Restifo NP. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. Journal of Immunology (Baltimore, Md. : 1950). 170: 1579-85. PMID 12538723 DOI: 10.4049/Jimmunol.170.3.1579  0.453
2003 Javia LR, Rosenberg SA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 85-93. PMID 12514432 DOI: 10.1097/00002371-200301000-00009  0.398
2002 Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. Journal of Immunology (Baltimore, Md. : 1950). 169: 6036-47. PMID 12421991 DOI: 10.4049/jimmunol.169.10.6036  0.481
2002 Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, ... Rosenberg SA, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York, N.Y.). 298: 850-4. PMID 12242449 DOI: 10.1126/Science.1076514  0.491
2002 Touloukian CE, Leitner WW, Robbins PF, Li YF, Kang X, Lapointe R, Hwu P, Rosenberg SA, Restifo NP. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Research. 62: 5144-7. PMID 12234976  0.518
2002 Weinreich DM, Rosenberg SA. Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: 185-7. PMID 12074048 DOI: 10.1097/00002371-200203000-00006  0.312
2002 Khong HT, Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy Cancer Research. 62: 3020-3023. PMID 12036907  0.361
2002 Marroquin CE, Westwood JA, Lapointe R, Mixon A, Wunderlich JR, Caron D, Rosenberg SA, Hwu P. Mobilization of dendritic cell precursors in patients with cancer by Flt3 ligand allows the generation of higher yields of cultured dendritic cells Journal of Immunotherapy. 25: 278-288. PMID 12000870 DOI: 10.1097/00002371-200205000-00011  0.435
2002 Seiter S, Monsurro V, Nielsen MB, Wang E, Provenzano M, Wunderlich JR, Rosenberg SA, Marincola FM. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: 252-63. PMID 12000867  0.491
2002 Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, ... Rosenberg SA, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: 243-51. PMID 12000866 DOI: 10.1097/00002371-200205000-00007  0.428
2002 Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, Schwartzentruber DJ. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: 82-7. PMID 11924913 DOI: 10.1097/00002371-200201000-00009  0.308
2002 Thurber SE, Khong HT, Kammula US, Rosenberg SA. Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: 63-71. PMID 11924911 DOI: 10.1097/00002371-200201000-00007  0.435
2002 McKee MD, Cecco SA, Niemela JE, Cormier J, Kim CJ, Steinberg SM, Rehak NN, Elin RJ, Rosenberg SA. Effects of interleukin 2 therapy on lymphocyte magnesium levels. The Journal of Laboratory and Clinical Medicine. 139: 5-12. PMID 11873239 DOI: 10.1067/MLC.2002.120361  0.34
2002 Rosenberg SA, Tong-On P, Li Y, Riley JP, El-Gamil M, Parkhurst MR, Robbins PF. Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 168: 2402-7. PMID 11859131 DOI: 10.4049/jimmunol.168.5.2402  0.433
2002 Khong HT, Rosenberg SA. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 168: 951-6. PMID 11777994 DOI: 10.4049/jimmunol.168.2.951  0.402
2002 Harada M, Li YF, El-Gamil M, Ohnmacht GA, Rosenberg SA, Robbins PF. Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 323-33. PMID 11565834 DOI: 10.1097/00002371-200107000-00008  0.471
2002 Seiter S, Monsurro V, Nielsen M, Wang E, Provenzano M, Wunderlich JR, Rosenberg SA, Marincola FM. Frequency of MART-1/MelanA and gp100/PMel17-Specific T Cells in Tumor Metastases and Cultured Tumor-Infiltrating Lymphocytes Journal of Immunotherapy. 25: 252-263. DOI: 10.1097/00002371-200205000-00008  0.315
2002 Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella Typhimurium Journal of Immunotherapy. 25: 218-225. DOI: 10.1097/00002371-200205000-00004  0.369
2001 Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity Journal of Immunology. 167: 6356-6365. PMID 11714800 DOI: 10.4049/jimmunol.167.11.6356  0.33
2001 Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 363-73. PMID 11565838 DOI: 10.1097/00002371-200107000-00012  0.399
2001 Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 3477-82. PMID 11481353 DOI: 10.1200/JCO.2001.19.15.3477  0.357
2001 Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM. Short-term kinetics of tumor antigen expression in response to vaccination. Journal of Immunology (Baltimore, Md. : 1950). 167: 1809-20. PMID 11466407 DOI: 10.4049/jimmunol.167.3.1809  0.428
2001 Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, McIntyre LS, Goodwin RS, Muehlbauer PM, Morton KE, Rogers-Freezer LJ, Seipp CA, Rosenberg SA, Marincola FM. A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Nystatin on the Development of Oral Irritation in Patients Receiving High-Dose Intravenous Interleukin-2. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 24: 188-192. PMID 11449076 DOI: 10.1097/00002371-200103000-00014  0.311
2001 Riley JP, Rosenberg SA, Parkhurst MR. Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 24: 212-220. PMID 11395636  0.351
2001 Riley JP, Rosenberg SA, Parkhurst MR. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase Journal of Immunotherapy. 24: 212-220. PMID 11394498 DOI: 10.1097/00002371-200105000-00004  0.361
2001 Rosenberg SA. Progress in human tumour immunology and immunotherapy Nature. 411: 380-384. PMID 11357146 DOI: 10.1038/35077246  0.395
2001 Monsurrò V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM. Kinetics of TCR use in response to repeated epitope-specific immunization. Journal of Immunology (Baltimore, Md. : 1950). 166: 5817-25. PMID 11313426 DOI: 10.4049/jimmunol.166.9.5817  0.303
2001 Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 151-61. PMID 11265773 DOI: 10.1097/00002371-200103000-00010  0.314
2001 Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proceedings of the National Academy of Sciences of the United States of America. 98: 3964-9. PMID 11259659 DOI: 10.1073/pnas.061507398  0.474
2001 Bownds S, Tong-On P, Rosenberg SA, Parkhurst M. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution Journal of Immunotherapy. 24: 1-9. PMID 11211143 DOI: 10.1097/00002371-200101000-00001  0.402
2001 Kawakami Y, Wang X, Shofuda T, Sumimoto H, Tupesis J, Fitzgerald E, Rosenberg S. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 166: 2871-7. PMID 11160356 DOI: 10.4049/jimmunol.166.4.2871  0.66
2001 Fritsch M, Rosenberg SA, Duray PH. Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 557-69. PMID 11001549 DOI: 10.1097/00002371-200009000-00006  0.477
2001 VASSELLI JR, YANG JC, LINEHAN WM, WHITE DE, ROSENBERG SA, WALTHER MM. LACK OF RETROPERITONEAL LYMPHADENOPATHY PREDICTS SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Journal of Urology. 166: 68-72. DOI: 10.1016/S0022-5347(05)66078-8  0.343
2000 Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Human Gene Therapy. 11: 2377-87. PMID 11096442 DOI: 10.1089/104303400750038480  0.504
2000 Kammula US, Marincola FM, Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. Journal of the National Cancer Institute. 92: 1336-44. PMID 10944556 DOI: 10.1093/JNCI/92.16.1336  0.314
2000 Nielsen MB, Monsurro V, Migueles SA, Wang E, Perez-Diez A, Lee KH, Kammula U, Rosenberg SA, Marincola FM. Status of activation of circulating vaccine-elicited CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 165: 2287-96. PMID 10925318 DOI: 10.4049/jimmunol.165.4.2287  0.388
2000 McKee MD, Clay TM, Diamond RA, Rosenberg SA, Nishimura MI. Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 419-29. PMID 10916751 DOI: 10.1097/00002371-200007000-00005  0.305
2000 Stewart JH, Rosenberg SA. Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 401-4. PMID 10916748 DOI: 10.1097/00002371-200007000-00002  0.333
2000 Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. Journal of Immunology (Baltimore, Md. : 1950). 165: 1153-9. PMID 10878395 DOI: 10.4049/Jimmunol.165.2.1153  0.467
2000 Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. International Journal of Cancer. 86: 818-26. PMID 10842196 DOI: 10.1002/(SICI)1097-0215(20000615)86:6<818::AID-IJC10>3.0.CO;2-W  0.391
2000 Marroquin CE, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ. Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 387-92. PMID 10838668 DOI: 10.1097/00002371-200005000-00012  0.344
2000 Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 1954-9. PMID 10784637 DOI: 10.1200/JCO.2000.18.9.1954  0.358
2000 Panelli MC, Bettinotti MP, Lally K, Ohnmacht GA, Li Y, Robbins P, Riker A, Rosenberg SA, Marincola FM. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. Journal of Immunology (Baltimore, Md. : 1950). 164: 4382-92. PMID 10754339 DOI: 10.4049/Jimmunol.164.8.4382  0.4
2000 Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice Journal of Immunology. 164: 3535-3542. PMID 10725708 DOI: 10.4049/Jimmunol.164.7.3535  0.439
2000 Ladányi A, Nishimura MI, Rosenberg SA, Yang JC. Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 36-47. PMID 10687136 DOI: 10.1097/00002371-200001000-00006  0.442
2000 Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 17-27. PMID 10687134 DOI: 10.1097/00002371-200001000-00004  0.576
2000 Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, Marincola FM. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. Journal of Immunology (Baltimore, Md. : 1950). 164: 495-504. PMID 10605047 DOI: 10.4049/jimmunol.164.1.495  0.377
2000 Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 2105-16. PMID 10561265 DOI: 10.1200/JCO.1999.17.7.2105  0.346
1999 Rosenberg SA. A new era of cancer immunotherapy: Converting theory to performance Ca-a Cancer Journal For Clinicians. 49: 70-73. PMID 11198888 DOI: 10.3322/Canjclin.49.2.70  0.359
1999 Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP, Irivine KR. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. Journal of Immunotherapy (Hagerstown, Md. : 1997). 22: 489-96. PMID 10570747 DOI: 10.1097/00002371-199911000-00003  0.358
1999 Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunological Reviews. 170: 85-100. PMID 10566144 DOI: 10.1111/j.1600-065X.1999.tb01331.x  0.492
1999 Riker AI, Panelli MC, Kammula US, Wang E, Wunderlich J, Abati A, Fetsch P, Rosenberg SA, Marincola FM. Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. Cancer Detection and Prevention. 23: 387-96. PMID 10468890 DOI: 10.1046/J.1525-1500.1999.99045.X  0.442
1999 Hurst R, White DE, Heiss J, Lee DS, Rosenberg SA, Schwartzentruber DJ. Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? Journal of Immunotherapy (Hagerstown, Md. : 1997). 22: 356-62. PMID 10404437 DOI: 10.1097/00002371-199907000-00009  0.362
1999 Dudley ME, Nishimura MI, Holt AK, Rosenberg SA. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. Journal of Immunotherapy (Hagerstown, Md. : 1997). 22: 288-98. PMID 10404430 DOI: 10.1097/00002371-199907000-00002  0.408
1999 Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA, Yang JC. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. The Journal of Urology. 162: 43-5. PMID 10379736 DOI: 10.1097/00005392-199907000-00011  0.316
1999 Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (New York, N.Y.). 284: 1351-4. PMID 10334988 DOI: 10.1126/SCIENCE.284.5418.1351  0.447
1999 Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. The Journal of Experimental Medicine. 189: 1659-68. PMID 10330445 DOI: 10.1084/jem.189.10.1659  0.466
1999 Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens Immunity. 10: 281-287. PMID 10204484 DOI: 10.1016/S1074-7613(00)80028-X  0.316
1999 Kim CJ, Chan CC, Rosenberg SA. Ophthalmologic evaluation in patients undergoing immunization with melanoma-associated antigens. Journal of Immunotherapy (Hagerstown, Md. : 1997). 22: 182-3. PMID 10093043 DOI: 10.1097/00002371-199903000-00010  0.339
1999 McKee MD, Clay TM, Rosenberg SA, Nishimura MI. Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 22: 93-102. PMID 10093034 DOI: 10.1097/00002371-199903000-00001  0.428
1999 Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 96: 2982-7. PMID 10077623 DOI: 10.1073/Pnas.96.6.2982  0.431
1999 Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 968-75. PMID 10071291 DOI: 10.1200/jco.1999.17.3.968  0.328
1999 Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. The Journal of Experimental Medicine. 189: 757-66. PMID 10049939 DOI: 10.1084/Jem.189.5.757  0.484
1999 Restifo NP, Rosenberg SA. Developing recombinant and synthetic vaccines for the treatment of melanoma Current Opinion in Oncology. 11: 50-57. PMID 9914879 DOI: 10.1097/00001622-199901000-00012  0.353
1999 Riker A, Cormier JN, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S, Marincola F. Immune selection after antigen-specific immunotherapy of melanoma. Surgery. 126: 112-120. DOI: 10.1016/S0039-6060(99)70143-1  0.358
1999 Rosenberg S, Yang J, White D, Steinberg S. Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response Journal of Urology. 162: 637-637. DOI: 10.1016/S0022-5347(05)68669-7  0.361
1998 Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. Journal of the National Cancer Institute. 90: 1894-900. PMID 9862627 DOI: 10.1093/Jnci/90.24.1894  0.392
1998 Nishimura MI, Custer MC, Schwarz SL, Parker LL, Mixon A, Clay TM, Yannelli JR, Rosenberg SA. T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 352-62. PMID 9789197 DOI: 10.1097/00002371-199809000-00003  0.49
1998 Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Annals of Surgery. 228: 307-19. PMID 9742914 DOI: 10.1097/00000658-199809000-00004  0.371
1998 Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 83: 797-805. PMID 9708948 DOI: 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M  0.342
Show low-probability matches.